<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="letter">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">V7ZxxsNCz9bPBPbB6CyBzSr</article-id>
      <article-id pub-id-type="other">00010</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000500010</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09600510</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000046</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Avalia&#231;&#227;o progn&#243;stica da doen&#231;a coron&#225;ria est&#225;vel atrav&#233;s de um novo escore</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Storti</surname>
            <given-names>Fernanda Coutinho</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moffa</surname>
            <given-names>Paulo Jorge</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Uchida</surname>
            <given-names>Augusto H.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hueb</surname>
            <given-names>Whady Armindo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>C&#233;sar</surname>
            <given-names>Luiz Ant&#244;nio Machado</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferreira</surname>
            <given-names>Beatriz Moreira Ayub</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Camargo Jr</surname>
            <given-names>Paulo Augusto de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chalela</surname>
            <given-names>William Azem</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Instituto do Cora&#231;&#227;o </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>05</month>
        <year>2011</year>
      </pub-date>
      <volume>96</volume>
      <issue>5</issue>
      <fpage>411</fpage>
      <lpage>419</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>05</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>01</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>22</day>
          <month>09</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A necessidade de melhorar a acur&#225;cia do teste de esfor&#231;o, determinou o desenvolvimento de escores, cuja aplicabilidade j&#225; foi amplamente reconhecida. OBJETIVO: Avalia&#231;&#227;o progn&#243;stica do coronariopata est&#225;vel atrav&#233;s de um novo escore simplificado. M&#201;TODOS: Um novo escore foi aplicado em 372 coronariopatas multiarteriais e fun&#231;&#227;o ventricular preservada, 71,8% homens, idade m&#233;dia 59,5 (&#177; 9,07) anos, randomizados para angioplastia, revasculariza&#231;&#227;o cir&#250;rgica e tratamento cl&#237;nico, acompanhados por 5 anos. &#211;bito cardiovascular foi o desfecho prim&#225;rio. Infarto do mioc&#225;rdio n&#227;o-fatal, &#243;bito e re-interven&#231;&#227;o formaram o desfecho combinado secund&#225;rio. O escore baseou-se numa equa&#231;&#227;o previamente validada resultante da soma de 1 ponto para: sexo masculino, hist&#243;ria de infarto, angina, diabete, uso de insulina e ainda 1 ponto para cada d&#233;cada de vida a partir dos 40 anos. Teste positivo adicionou 1 ponto. RESULTADOS: Ocorreram 36 &#243;bitos (10 no grupo angioplastia, 15 no grupo revasculariza&#231;&#227;o e 11 no grupo cl&#237;nico), p = 0,61. Observou-se 93 eventos combinados: 37 no grupo angioplastia, 23 no grupo revasculariza&#231;&#227;o e 33 no grupo cl&#237;nico (p = 0,058). 247 pacientes apresentaram escore cl&#237;nico &gt; 5 pontos e 216 &gt; 6 pontos. O valor de corte &gt; 5 ou &gt; 6 pontos identificou maior risco, com p = 0,015 e p = 0,012, respectivamente. A curva de sobrevida mostrou uma incid&#234;ncia de &#243;bito ap&#243;s a randomiza&#231;&#227;o diferente naqueles com escore &gt; 6 pontos (p = 0,07), e uma incid&#234;ncia de eventos combinados diferente entre pacientes com escore &lt; 6 e &gt; 6 pontos (p = 0,02). CONCLUS&#195;O: O novo escore demonstrou consist&#234;ncia na avalia&#231;&#227;o progn&#243;stica do coronariopata est&#225;vel multiarterial.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Teste de esfor&#231;o</kwd>
        <kwd>doen&#231;a das coron&#225;rias</kwd>
        <kwd>angina pectoris</kwd>
        <kwd>progn&#243;stico</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>15</day>
        <month>04</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO ORIGINAL</bold>
    </p>
    <p>Avalia&#231;&#227;o progn&#243;stica da doen&#231;a coron&#225;ria est&#225;vel atrav&#233;s de um novo escore</p>
    <p>
      <bold>Fernanda Coutinho Storti; Paulo Jorge Moffa; Augusto H. Uchida; Whady Armindo Hueb; Luiz Ant&#244;nio Machado C&#233;sar; Beatriz Moreira Ayub Ferreira; Paulo Augusto de Camargo Jr; William Azem Chalela</bold>
    </p>
    <p> Instituto do Cora&#231;&#227;o - HCFMUSP - S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A necessidade de melhorar a acur&#225;cia do teste de esfor&#231;o, determinou o desenvolvimento de escores, cuja aplicabilidade j&#225; foi amplamente reconhecida. </p>
    <p><bold>OBJETIVO:</bold> Avalia&#231;&#227;o progn&#243;stica do coronariopata est&#225;vel atrav&#233;s de um novo escore simplificado. </p>
    <p><bold>M&#201;TODOS:</bold> Um novo escore foi aplicado em 372 coronariopatas multiarteriais e fun&#231;&#227;o ventricular preservada, 71,8% homens, idade m&#233;dia 59,5 (&#177; 9,07) anos, randomizados para angioplastia, revasculariza&#231;&#227;o cir&#250;rgica e tratamento cl&#237;nico, acompanhados por 5 anos. &#211;bito cardiovascular foi o desfecho prim&#225;rio. Infarto do mioc&#225;rdio n&#227;o-fatal, &#243;bito e re-interven&#231;&#227;o formaram o desfecho combinado secund&#225;rio. O escore baseou-se numa equa&#231;&#227;o previamente validada resultante da soma de 1 ponto para: sexo masculino, hist&#243;ria de infarto, angina, diabete, uso de insulina e ainda 1 ponto para cada d&#233;cada de vida a partir dos 40 anos. Teste positivo adicionou 1 ponto. </p>
    <p><bold>RESULTADOS:</bold> Ocorreram 36 &#243;bitos (10 no grupo angioplastia, 15 no grupo revasculariza&#231;&#227;o e 11 no grupo cl&#237;nico), p = 0,61. Observou-se 93 eventos combinados: 37 no grupo angioplastia, 23 no grupo revasculariza&#231;&#227;o e 33 no grupo cl&#237;nico (p = 0,058). 247 pacientes apresentaram escore cl&#237;nico &gt; 5 pontos e 216 &gt; 6 pontos. O valor de corte &gt; 5 ou &gt; 6 pontos identificou maior risco, com p = 0,015 e p = 0,012, respectivamente. A curva de sobrevida mostrou uma incid&#234;ncia de &#243;bito ap&#243;s a randomiza&#231;&#227;o diferente naqueles com escore &gt; 6 pontos (p = 0,07), e uma incid&#234;ncia de eventos combinados diferente entre pacientes com escore &lt; 6 e &gt; 6 pontos (p = 0,02). </p>
    <p><bold>CONCLUS&#195;O:</bold> O novo escore demonstrou consist&#234;ncia na avalia&#231;&#227;o progn&#243;stica do coronariopata est&#225;vel multiarterial.</p>
    <p><bold>Palavras-chave:</bold> Teste de esfor&#231;o, doen&#231;a das coron&#225;rias, angina <italic>pectoris</italic>, progn&#243;stico.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Mesmo com os avan&#231;os da medicina, o teste de esfor&#231;o (TE) com seu baixo custo, seguran&#231;a e f&#225;cil aplicabilidade &#233; recomendado pela diretriz americana<sup>1</sup> como o primeiro procedimento a ser realizado em pacientes com doen&#231;a arterial coron&#225;ria (DAC). Assim, a maximiza&#231;&#227;o das informa&#231;&#245;es obtidas no TE &#233; de primordial import&#226;ncia e a necessidade de melhorar sua acur&#225;cia, determinou o desenvolvimento de escores, amplamente reconhecidos pela literatura cient&#237;fica<sup>2-9</sup>. </p>
    <p>Para uma abordagem mais did&#225;tica da DAC, tais escores foram classificados em: pr&#233;-teste, p&#243;s-teste, simplificados, multivariados, diagn&#243;sticos ou progn&#243;sticos. Num escore pr&#233;-teste, apenas vari&#225;veis cl&#237;nicas s&#227;o analisadas, ao incorporar par&#226;metros do TE define-se um escore p&#243;s-teste<sup>6</sup>. </p>
    <p>Dentre os escores pr&#233;-teste temos: Diamond-Forrester<sup>2</sup>, Morise e Jalisi<sup>3</sup>, Froelicher e cols.<sup>4</sup> e Hubbard e cols.<sup>10</sup>, entre outros. Essa an&#225;lise probabil&#237;stica preliminar &#233; recomendada pela diretriz americana<sup>1</sup> sobre TE. </p>
    <p>Entre os principais escores p&#243;s-teste temos: Mark e cols.<sup>7</sup>, Raxwal e cols.<sup>8</sup>, Morrow e cols.<sup>11</sup>, Froelicher e cols.<sup>4</sup>, Morise e cols.<sup>3</sup>, Do e cols.<sup>9</sup>, Morise e cols.<sup>6</sup>, Detrano e cols.<sup>12</sup>, Lu e cols.<sup>13</sup>, Villella e cols. (GISSI 2)<sup>14</sup>, Koide e cols.<sup>15</sup>, Hollenberg e cols.<sup>16</sup>.</p>
    <p>Escores baseados em equa&#231;&#245;es multivariadas possuem f&#243;rmulas complexas, das quais derivam escores simplificados cujos c&#225;lculos envolvem a simples somat&#243;ria de pontos. </p>
    <p>Escores diagn&#243;sticos visam a estimativa de probabilidade de DAC, podendo ter car&#225;ter progn&#243;stico quando realizam a estimativa de doen&#231;a grave (padr&#227;o triarterial ou les&#227;o de tronco de coron&#225;ria esquerda). Escores progn&#243;sticos s&#227;o idealizados para avalia&#231;&#227;o de risco, principalmente, de &#243;bito cardiovascular ou infarto n&#227;o-fatal.</p>
    <p>O escore progn&#243;stico mais utilizado &#233; o de Mark e cols. (Duke)<sup>17</sup>, e embora seja amplamente validado, n&#227;o classifica adequadamente assintom&#225;ticos, idosos, pacientes no p&#243;s-revasculariza&#231;&#227;o do mioc&#225;rdio (recente) e no p&#243;s-infarto do mioc&#225;rdio recente. Al&#233;m disso, ele &#233; composto exclusivamente por dados do TE, seus resultados e sua classifica&#231;&#227;o em categorias de risco s&#227;o complexos e de dif&#237;cil memoriza&#231;&#227;o. </p>
    <p>Um escore cl&#237;nico simplificado foi idealizado por Hubbard e cols.<sup>10</sup> com intuito diagn&#243;stico, sendo posteriormente validado<sup>18</sup> para an&#225;lise progn&#243;stica de DAC. Contudo, tal escore n&#227;o inclui uma prova documental de isquemia em sua composi&#231;&#227;o, dado que impacta no progn&#243;stico do portador de coronariopatia.</p>
    <p>Visando propiciar uma orienta&#231;&#227;o mais completa e objetiva &#224; estratifica&#231;&#227;o de risco do coronariopata est&#225;vel, propomos um novo escore p&#243;s-teste, que inclui o resultado do TE com os par&#226;metros do escore de Hubbard e cols.<sup>10</sup>. </p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>O estudo baseou-se numa an&#225;lise retrospectiva de dados coletados prospectivamente do estudo (MASS-II) Hueb e cols.<sup>19</sup>, com 05 anos de seguimento. MASS refere-se a sigla de <italic>Medicine, Angioplasty or Surgery Study</italic>, cujo objetivo era avaliar, randomicamente, o tratamento de portadores de coronariopatia est&#225;vel multiarterial e fun&#231;&#227;o ventricular preservada. O modelo do estudo, crit&#233;rios de sele&#231;&#227;o e procedimentos de randomiza&#231;&#227;o foram previamente publicados<sup>20</sup>. O estudo foi aprovado pelo comit&#234; cient&#237;fico e de &#233;tica e todos assinaram um consentimento livre e esclarecido. Todos os TE foram realizados em esteira rolante Fukuda Denshi STAR ML- 8000, com 15 deriva&#231;&#245;es simult&#226;neas e protocolo de Bruce<sup>21</sup>.</p>
    <p>Inicialmente, foram selecionados 611 pacientes, sendo que 18 pacientes n&#227;o realizaram o TE por motivos sociais, 58 tiveram o TE considerado como inconclusivo (presen&#231;a de bloqueio de ramo esquerdo, fibrila&#231;&#227;o atrial e sobrecarga ventricular esquerda) e em 163 pacientes, o exame foi considerado ineficaz, por n&#227;o atingir a frequ&#234;ncia card&#237;aca subm&#225;xima. </p>
    <p>Assim, a amostra final deste estudo incluiu 372 pacientes, todos com confirma&#231;&#227;o cinecoronariogr&#225;fica de doen&#231;a bi ou triarterial e fun&#231;&#227;o ventricular esquerda preservada, sendo 267 homens (71,8%), com idade m&#233;dia de 59,5 (&#177; 9,07) anos, distribu&#237;dos em tr&#234;s grupos: angioplastia transluminal coron&#225;ria (ATC) 34,4%, cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica (RM) 34,9% e tratamento cl&#237;nico (TC) 30,6%.</p>
    <p>O delineamento do estudo permitiu aos pacientes uma transloca&#231;&#227;o entre os diversos grupos de tratamento, baseados na ocorr&#234;ncia de sintomas, em qualquer &#233;poca do estudo. N&#227;o houve distin&#231;&#227;o nos tipos de medicamentos entre os tr&#234;s grupos.</p>
    <p>Os crit&#233;rios de inclus&#227;o foram:</p>
    <p>1. Angina est&#225;vel.</p>
    <p>2. Fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo (FEVE) considerada normal, avaliada pelo ecodopplercardiograma atrav&#233;s do m&#233;todo &#225;rea comprimento.</p>
    <p>3. Confirma&#231;&#227;o angiogr&#225;fica de DAC bi ou triarterial, com documenta&#231;&#227;o de obstru&#231;&#227;o luminal de pelo menos 70%, considerando-se somente ramos coron&#225;rios principais.</p>
    <p>Crit&#233;rios de n&#227;o-inclus&#227;o:</p>
    <p>1. Valvopatias.</p>
    <p>2. Aneurisma do ventr&#237;culo esquerdo.</p>
    <p>3. Disfun&#231;&#227;o ventricular esquerda.</p>
    <p>4. Acidente vascular encef&#225;lico pr&#233;vio.</p>
    <p>5. Limita&#231;&#227;o de an&#225;lise morfol&#243;gica para defini&#231;&#227;o de isquemia mioc&#225;rdica no eletrocardiograma: s&#237;ndrome de pr&#233;-excita&#231;&#227;o ventricular, bloqueio de ramo esquerdo al&#233;m de outros dist&#250;rbios da condu&#231;&#227;o intraventricular, sobrecarga ventricular esquerda, estimula&#231;&#227;o card&#237;aca artificial, etc.</p>
    <p>6. Incapacidade f&#237;sica de qualquer natureza.</p>
    <p>
      <bold>Escore cl&#237;nico simplificado ou escore de Hubbard</bold>
    </p>
    <p>O escore de Hubbard e cols.<sup>10</sup> foi validado retrospectivamente em uma popula&#231;&#227;o consecutiva e sintom&#225;tica, submetida &#224; investiga&#231;&#227;o de coronariopatia, atrav&#233;s de cintilografia mioc&#225;rdica e cinecoronariografia em at&#233; 6 meses. Atrav&#233;s da an&#225;lise de regress&#227;o log&#237;stica, selecionaram-se 5 vari&#225;veis, compondo um escore de 5 pontos que fornecia estimativas de coronariopatia severa, demonstrando que a gravidade da doen&#231;a aumenta em fun&#231;&#227;o da pontua&#231;&#227;o.</p>
    <p>Tal escore resulta da soma de 1 ponto para cada par&#226;metro: sexo masculino, hist&#243;ria de infarto do mioc&#225;rdio e/ou ondas Q no eletrocardiograma, angina t&#237;pica, diabete, uso de insulina e ainda pontua conforme a faixa et&#225;ria. At&#233; 39 anos n&#227;o se adiciona pontos, de 40 a 49 anos soma-se 1 ponto, 50 a 59 anos, 2 pontos, 60 a 69 anos, 3 pontos, 70 a 79 anos, 4 pontos e <underline>&gt;</underline> 80 anos, 5 pontos. </p>
    <p>O escore varia de zero a 10 pontos, estimando a probabilidade de coronariopatia em 3 grupos: alta (&gt; 5 pontos), intermedi&#225;ria (igual a 5 pontos) e baixa (&lt; 5 pontos).</p>
    <p>
      <bold>Desenvolvimento do novo escore</bold>
    </p>
    <p>O novo escore foi estruturado a partir da somat&#243;ria simples das vari&#225;veis do escore de Hubbard e cols.<sup>10</sup>, incorporando tamb&#233;m o resultado do TE. Quando o TE resultava positivo, adicionou-se 1 ponto. TE negativo n&#227;o determinou pontua&#231;&#227;o adicional. Assim, a pontua&#231;&#227;o total do novo escore variou de 0 a 11 pontos conforme ilustra a <xref ref-type="table" rid="tab01">tabela 1</xref>. O valor de corte considerado para alto risco de eventos e &#243;bito foi de 6 pontos, ap&#243;s an&#225;lise da curva de sobrevida.</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gt01.jpg"/></table-wrap>
    <p>Foi considerado teste positivo a presen&#231;a de depress&#227;o do segmento ST <underline>&gt;</underline> 1 mm, de morfologia horizontal ou descendente, durante ou ap&#243;s o exerc&#237;cio, sendo a magnitude do desn&#237;vel aferida a 80 ms do ponto J; ou presen&#231;a de eleva&#231;&#227;o do segmento ST <underline>&gt;</underline> 1,0 mm em deriva&#231;&#245;es sem ondas Q patol&#243;gicas, seguindo as recomenda&#231;&#245;es das diretrizes sobre TE<sup>1,22</sup>.</p>
    <p>O resultado positivo foi considerado como a prova documental da isquemia mioc&#225;rdica, adicionando um ponto no novo escore progn&#243;stico. O resultado negativo foi considerado como aus&#234;ncia de documenta&#231;&#227;o de isquemia mioc&#225;rdica e sem valor progn&#243;stico adicional no escore.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>A associa&#231;&#227;o entre o novo escore e cada um dos desfechos foi analisada pela regress&#227;o de Cox<sup>23</sup>, inclusive para identificar subgrupos de alto risco. A curva de sobrevida cardiovascular foi gerada de acordo com m&#233;todo de Kaplan-Meier<sup>24</sup> e o teste Log-Rank aplicado para comparar essas curvas de sobrevida. Para todas as an&#225;lises uma p &lt; 0,05 foi considerada estatisticamente significante.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Dos 372 pacientes estudados, 156 pacientes tinham hist&#243;ria de infarto do mioc&#225;rdio, 334 apresentavam angina pelo menos classe funcional II, 137 (36,8%) eram diab&#233;ticos, sendo 16 (0,11%) usu&#225;rios regulares de insulina. </p>
    <p>Durante o per&#237;odo total de seguimento, observaram-se 29 epis&#243;dios de infarto do mioc&#225;rdio n&#227;o-fatal, sendo 11 no grupo ATC, 6 no grupo RM e 12 no grupo TC, sendo essa diferen&#231;a entre os grupos considerada n&#227;o significativa (p = 0,21).</p>
    <p>Com rela&#231;&#227;o &#224; necessidade de RM ap&#243;s a randomiza&#231;&#227;o, observaram-se 06 casos no grupo ATC, 2 casos no grupo RM e 16 casos no grupo TC, sendo essa diferen&#231;a entre os grupos considerada significante (p = 0,001).</p>
    <p>A necessidade de ATC ap&#243;s a randomiza&#231;&#227;o foi observada em 18 casos no grupo ATC, 03 casos no grupo RM e em 04 casos no grupo TC, sendo essa diferen&#231;a entre os grupos considerada significante (p = 0,001).</p>
    <p>Foram observados 36 &#243;bitos durante o seguimento, sendo 10 no grupo ATC, 15 no grupo RM e em 11 casos no grupo TC, (p = 0,61). A incid&#234;ncia de &#243;bito ap&#243;s a randomiza&#231;&#227;o foi observada em 10 pacientes com escore &lt; 6 pontos e em 26 pacientes com escore <underline>&gt;</underline> 6 pontos (p = 0,07).</p>
    <p>O total de eventos combinados foi de 93, com a seguinte distribui&#231;&#227;o entre os grupos: 37 no grupo ATC, 23 no grupo RM e 33 no grupo TC, com diferen&#231;a marginalmente significante (p = 0,058). A incid&#234;ncia de eventos combinados ap&#243;s a randomiza&#231;&#227;o foi observada em 34 pacientes com escore &lt; 6 pontos e em 59 pacientes com escore <underline>&gt;</underline> 6 pontos (p = 0,22).</p>
    <p>Quando se avaliou a idade, para os diferentes grupos, n&#227;o se observou diferen&#231;a significativa (p = 0,73), com idade m&#233;dia de 59,75 &#177; 9,5 anos para o grupo ATC (127 pacientes), 59,97 &#177; 8,4 anos para o grupo RM (130 pacientes), 59,08 &#177; 9,3 anos para o grupo TC (115 pacientes).</p>
    <p>Com rela&#231;&#227;o ao sexo, um escore inferior a 06 pontos foi observado em 97 homens e em 59 mulheres. Escore <underline>&gt;</underline> 06 pontos foi observado em 169 homens e em 47 mulheres. </p>
    <p>A necessidade de RM ap&#243;s a randomiza&#231;&#227;o foi observada em 8 pacientes com escore &lt; 6 pontos e em 16 pacientes com escore <underline>&gt;</underline> 6 pontos (p = 0,37).</p>
    <p>A necessidade de ATC ap&#243;s a randomiza&#231;&#227;o foi observada em 12 pacientes com escore &lt; 6 pontos e em 13 pacientes com escore <underline>&gt;</underline> 6 pontos (p = 0,52).</p>
    <p>A an&#225;lise pela curva de sobrevida demonstrou que houve diferen&#231;a marginalmente significante na incid&#234;ncia de eventos combinados para os pacientes com escore de Hubbard &lt; 5 ou <underline>&gt;</underline> 5 pontos (p = 0,062), (<xref ref-type="fig" rid="fig01">Figura 1</xref>).</p>
    <fig id="fig01">
      <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf01.jpg"/></fig>
    <p>Quando se avaliou a incid&#234;ncia de eventos combinados para o novo escore, houve diferen&#231;a estatisticamente significante (p = 0,02) entre os pacientes com escore &lt; 6 e <underline>&gt;</underline> 6 pontos, conforme ilustram as respectivas curvas comparativas de sobrevida da <xref ref-type="fig" rid="fig02">figura 2</xref>. </p>
    <fig id="fig02">
      <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf02.jpg"/></fig>
    <p>A incid&#234;ncia de &#243;bito cardiovascular foi maior nos pacientes com escore <underline>&gt;</underline> 5 pontos pelo escore de Hubbard (p = 0,015), <xref ref-type="fig" rid="fig03">figura 3</xref>. A diferen&#231;a na incid&#234;ncia de &#243;bito foi mais significante entre os pacientes com escore &lt; 6 e <underline>&gt;</underline> 6 pontos, com p = 0,004, <xref ref-type="fig" rid="fig04">figura 4</xref>.</p>
    <fig id="fig03">
      <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf03.jpg"/></fig>
    <fig id="fig04">
      <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf04.jpg"/></fig>
    <p>Comparando os dois escores, observou-se que 31 pacientes foram classificados com alto risco pelo escore de Hubbard, mas, considerados como baixo risco pelo novo escore. Nenhum indiv&#237;duo de baixo risco pelo escore de Hubbard foi classificado como de alto risco no novo escore, conforme ilustra a <xref ref-type="table" rid="tab02">tabela 2</xref>. A diferen&#231;a da classifica&#231;&#227;o de risco entre os escores foi considerada estatisticamente significante (p = 0,001). Do total de pacientes analisados, 247 (66,4%) apresentaram escore de Hubbard <underline>&gt;</underline> 5 pontos e 216 (58%) <underline>&gt;</underline> 6 pontos, como demonstra a <xref ref-type="table" rid="tab02">tabela 2</xref>. O valor de corte <underline>&gt;</underline> 5 ou <underline>&gt;</underline> 6 pontos identificou indiv&#237;duos de maior risco de &#243;bito, com p = 0,015 e p = 0,004, respectivamente.</p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gt02.jpg"/></table-wrap>
    <p>Em rela&#231;&#227;o ao desfecho prim&#225;rio, a an&#225;lise da curva de sobrevida n&#227;o demonstrou diferen&#231;a entre os tr&#234;s grupos de tratamento, <xref ref-type="fig" rid="fig05">figura 5</xref>.</p>
    <fig id="fig05">
      <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf05.jpg"/></fig>
    <p>Em rela&#231;&#227;o &#224; incid&#234;ncia de &#243;bito e escore de Hubbard <underline>&gt;</underline> 5, observaram-se 15 &#243;bitos no grupo ATC, 12 no grupo RM e 10 no grupo TC, (p = 0,59), enquanto que com escore &lt; 5 pontos, observamos 1 &#243;bito no grupo ATC, 5 no grupo RM e 3 no grupo TC (p = 0,176). </p>
    <p>Em rela&#231;&#227;o &#224; incid&#234;ncia de &#243;bito e novo escore <underline>&gt;</underline> 6, observaram-se 11 &#243;bitos no grupo ATC, 7 no grupo RM e 6 no grupo TC, (p = 0,4). Na presen&#231;a de novo escore &lt; 6 pontos evidenciaram-se 1 &#243;bito no grupo ATC, 6 no grupo RM e 3 no grupo TC (p = 0,163). </p>
    <p>Quanto &#224; ocorr&#234;ncia de eventos combinados nos pacientes com escore de Hubbard <underline>&gt;</underline> 5 pontos, observaram-se 33 eventos no grupo ATC, 13 no grupo RM e 23 no grupo TC, com uma incid&#234;ncia de eventos significantemente reduzida no grupo RM (p &lt; 0,001). A an&#225;lise da incid&#234;ncia de eventos combinados nos pacientes com escore de Hubbard &lt; 5 pontos, mostrou 1 evento no grupo ATC, 5 eventos no grupo RM e 3 no grupo TC (p = 0,24).</p>
    <p>Ao analisar a incid&#234;ncia de eventos combinados nos pacientes com novo escore <underline>&gt;</underline> 6 pontos, observaram-se 24 eventos no grupo ATC, 8 no grupo RM e 12 no grupo TC (p = 0,001). Nos pacientes com escore &lt; 6 pontos observamos 9 eventos no grupo ATC, 5 no grupo RM e 9 no grupo TC (p = 0,334).</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A avalia&#231;&#227;o progn&#243;stica &#233; um componente crucial da avalia&#231;&#227;o cl&#237;nica da DAC. Embora os pacientes com angina est&#225;vel apresentem baixa mortalidade<sup>25-27</sup>, o risco de infarto do mioc&#225;rdio, a necessidade de interven&#231;&#245;es e os sintomas impactam a evolu&#231;&#227;o cl&#237;nica de maneira representativa. </p>
    <p>V&#225;rios escores foram desenvolvidos para estratifica&#231;&#227;o de DAC adotando-se par&#226;metros cl&#237;nicos e do TE ou combinados<sup>28,29</sup>, contudo, escores progn&#243;sticos no portador de angina est&#225;vel s&#227;o escassos<sup>30</sup>.</p>
    <p>A proposta desse estudo foi desenvolver um &#237;ndice para estratifica&#231;&#227;o de risco do coronariopata est&#225;vel multiarterial, atrav&#233;s de um m&#233;todo simples e acess&#237;vel, contrastando com a ampla gama de procedimentos de alto custo dispon&#237;veis. </p>
    <p>Em nossa casu&#237;stica, a idade m&#233;dia de 59,5 anos, determinou um maior valor inicial do escore. Assim, nossa amostra foi representada por indiv&#237;duos com uma faixa et&#225;ria maior, portanto, com um perfil de maior risco. O predom&#237;nio masculino na amostra estudada n&#227;o impactou a interpreta&#231;&#227;o dos resultados devido a documenta&#231;&#227;o de DAC multiarterial em ambos os sexos.</p>
    <p>A maioria dos homens (63,29%) apresentou escore <underline>&gt;</underline> 6 pontos, enquanto na maioria das mulheres foi observado um escore &lt; 6 pontos. A pontua&#231;&#227;o maior para os homens pode estar relacionada ao fato de que o sexo masculino j&#225; define uma pontua&#231;&#227;o adicional. Al&#233;m disso, infarto do mioc&#225;rdio &#233; mais comum em homens, por&#233;m as mulheres apresentam um progn&#243;stico pior, devido a maior taxa de &#243;bito e re-infarto<sup>31</sup>. Quanto a dor precordial, embora ela seja mais frequente nas mulheres, a preval&#234;ncia de DAC significante &#233; menor, determinando um valor preditivo menor para os testes n&#227;o-invasivos<sup>32,33</sup>.</p>
    <p>A an&#225;lise progn&#243;stica n&#227;o considerou a diferen&#231;a entre os padr&#245;es angiogr&#225;ficos bi ou triarterial devido a um baixo n&#250;mero de desfechos no per&#237;odo de seguimento.</p>
    <p>A taxa de &#243;bitos (10,33%) em nossa casu&#237;stica foi superior &#224; mortalidade geral de pacientes com angina est&#225;vel, que est&#225; ao redor de 1% ao ano segundo dados da diretriz sobre angina est&#225;vel<sup>33</sup>. Isto pode ser explicado pela presen&#231;a de um maior n&#250;mero de pacientes de alto risco em nosso estudo, com maior preval&#234;ncia de multiarteriais e de diab&#233;ticos, apesar da fun&#231;&#227;o ventricular esquerda preservada. </p>
    <p>A incid&#234;ncia de eventos combinados e a necessidade de re-interven&#231;&#227;o com angioplastia ap&#243;s a randomiza&#231;&#227;o foi maior no grupo ATC. Provavelmente, isto est&#225; relacionado a uma maior taxa de reestenose, j&#225; que uma parte representativa de nossa amostra possui diabete. Taxas maiores de reestenose s&#227;o comumente encontradas nos diab&#233;ticos<sup>34</sup>. </p>
    <p>A alta taxa de diab&#233;ticos (36,8%) determinou tamb&#233;m uma maior pontua&#231;&#227;o inicial no escore. Compat&#237;vel com o fato de que os portadores de diabete possuem maior incid&#234;ncia de coronariopatia grave. Est&#225; bem definido que o diabete &#233; um fator de risco maior para eventos coron&#225;rios<sup>35</sup>. O diabete tipo 2 &#233; de particular import&#226;ncia, pois, &#233; mais comum e ocorre frequentemente em idosos, quando m&#250;ltiplos fatores de risco coexistem. </p>
    <p>Em rela&#231;&#227;o ao TE, os diab&#233;ticos representam um grupo particularizado: h&#225; uma maior incid&#234;ncia de hipertens&#227;o arterial, vasculopatia perif&#233;rica, neuropatia perif&#233;rica, obesidade e menor capacidade funcional. Al&#233;m disso, est&#227;o mais expostos ao uso de medicamentos que limitam a frequ&#234;ncia card&#237;aca. Assim, quando m&#250;ltiplos fatores de risco coexistem, h&#225; limita&#231;&#227;o para que se atinja um baixo risco no escore de Duke. Adicionalmente, o n&#237;vel de trabalho alcan&#231;ado pode n&#227;o ser suficiente para a documenta&#231;&#227;o de isquemia mioc&#225;rdica, mesmo com eventual DAC significante.</p>
    <p>O escore de Hubbard foi selecionado inicialmente para compor o novo escore, pois, cont&#234;m vari&#225;veis de f&#225;cil avalia&#231;&#227;o. O n&#250;mero de vari&#225;veis &#233; pequeno, a somat&#243;ria dos pontos &#233; simplificada e de f&#225;cil interpreta&#231;&#227;o, possuindo correla&#231;&#227;o linear entre o resultado e o progn&#243;stico. Al&#233;m disso, pode identificar indiv&#237;duos de alto risco, mesmo quando classificados em baixo risco pelo escore de Duke<sup>36</sup>. Contudo, ele possui limita&#231;&#245;es, como a an&#225;lise exclusiva de vari&#225;veis cl&#237;nicas, n&#227;o considerando uma prova documental de isquemia mioc&#225;rdica que comprovadamente fornece informa&#231;&#227;o progn&#243;stica adicional<sup>37</sup>. </p>
    <p>Ao acrescentar essa vari&#225;vel na an&#225;lise, 31 pacientes foram classificados como baixo risco pelo novo escore, pois apresentavam teste ergom&#233;trico negativo. Assim, o escore de Hubbard pode ter superestimado o grupo de maior risco na popula&#231;&#227;o estudada. </p>
    <p>No TE, embora outras vari&#225;veis como capacidade funcional, arritmias, respostas cronotr&#243;pica e inotr&#243;pica, sejam consideradas de maior valor preditivo do que a depress&#227;o do segmento ST, existe um v&#237;cio de interpreta&#231;&#227;o dos v&#225;rios estudos. N&#227;o se considerou que na pr&#225;tica cl&#237;nica um TE positivo acaba implicando na indica&#231;&#227;o de estudo cineangiocoronariogr&#225;fico e, consequentemente, de tratamento farmacol&#243;gico ou procedimentos de revasculariza&#231;&#227;o mioc&#225;rdica (cir&#250;rgica ou percut&#226;nea). Tais interven&#231;&#245;es terap&#234;uticas determinam uma altera&#231;&#227;o na evolu&#231;&#227;o natural da doen&#231;a coron&#225;ria que impacta no valor progn&#243;stico do marcador eletrocardiogr&#225;fico de isquemia mioc&#225;rdica.</p>
    <p>A an&#225;lise progn&#243;stica do novo escore n&#227;o incorporou essas in&#250;meras vari&#225;veis espec&#237;ficas do TE, adotando somente a presen&#231;a de documenta&#231;&#227;o eletrocardiogr&#225;fica de isquemia mioc&#225;rdica, pois o objetivo foi aplicar um sistema pr&#225;tico, de f&#225;cil memoriza&#231;&#227;o e interpreta&#231;&#227;o, para que ele seja mais amplamente aceito tanto pelo cl&#237;nico quanto pelo especialista.</p>
    <p>Com o uso de escores progn&#243;sticos simplificados aplicados em associa&#231;&#227;o ao TE podemos estratificar de forma mais acurada o coronariopata est&#225;vel, reduzindo a taxa de solicita&#231;&#227;o de procedimentos de alta complexidade.</p>
    <p>Escores melhoram a acur&#225;cia progn&#243;stica do TE, diminuem v&#237;cios de interpreta&#231;&#227;o e organizam as diversas informa&#231;&#245;es cl&#237;nicas, determinando uma redu&#231;&#227;o na subjetividade e na variabilidade da estratifica&#231;&#227;o de risco. Particularmente, o escore proposto por este estudo demonstrou seu valor progn&#243;stico de forma abrangente, atrav&#233;s de uma sistem&#225;tica simples e organizada. </p>
    <p>
      <bold>Conclus&#245;es</bold>
    </p>
    <p>Este novo escore &#233; um m&#233;todo objetivo e simples para estratifica&#231;&#227;o de risco do coronariopata est&#225;vel.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de doutorado de Fernanda Coutinho Storti pelo InCor - HCFMUSP.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p>Fernanda Coutinho Storti </p>
        <p> Rua Doutor Alberto Torres, 16/61 - Perdizes </p>
        <p> 05006-030 - S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="storti@cardiol.br">storti@cardiol.br</email>, </p>
        <p>
          <email xlink:href="fcstorti@hotmail.com">fcstorti@hotmail.com</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 30/05/10; revisado recebido em 22/09/10; aceito em 11/01/11.</p>
    <p>Full texts in English - <ext-link ext-link-type="uri" xlink:href="http://www.arquivosonline.com.br">http://www.arquivosonline.com.br</ext-link></p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Gibbons RJ, Balady GJ, Bricker JT, Chaitman     BR, Fletcher GF, Froelicher VF, Mark DB, et al. American College of Cardiology/American     Heart Association Task Force on Practice Guidelines (Committee to Update     the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guideline update for     exercise testing: summary article: a report of the American College of Cardiology/American     Heart Association Task Force on Practice Guidelines (Committee to Update     the 1997 Exercise Testing Guidelines). Circulation. 2002;106(14):1883-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines): ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines)</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1883</fpage>
          <lpage>92</lpage>
          <issue>14</issue>
          <volume>106</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gibbons</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Balady</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Bricker</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Chaitman</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Froelicher</surname>
              <given-names>VF</given-names>
            </name>
            <name>
              <surname>Mark</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Diamond GA, Forrester JS. Analysis of     probability as an aid in the clinical diagnosis of coronary-artery disease.     N Engl J Med. 1979;300(24):1350-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1979</year>
          </date>
          <fpage>1350</fpage>
          <lpage>8</lpage>
          <issue>24</issue>
          <volume>300</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Diamond</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Forrester</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Morise AP, Jalisi F. Evaluation of pretest     and exercise test scores to assess all-cause mortality in unselected patients     presenting for exercise testing with symptoms of suspected coronary artery     disease. J Am Coll Cardiol. 2003;42(5):842-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evaluation of pretest and exercise test scores to assess all-cause mortality in unselected patients presenting for exercise testing with symptoms of suspected coronary artery disease</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>842</fpage>
          <lpage>50</lpage>
          <issue>5</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morise</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Jalisi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Ashley EA, Myers J, Froelicher V. Exercise     testing in clinical medicine. Lancet. 2000;356(9241):1592-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise testing in clinical medicine</article-title>
          <source>Lancet</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1592</fpage>
          <lpage>7</lpage>
          <issue>9241</issue>
          <volume>356</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ashley</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Froelicher</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Froelicher V, Shetler K, Ashley E. Better     decisions through science: exercise testing scores. Prog Cardiovasc Dis.     2002;44(5):395-414.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Better decisions through science: exercise testing scores</article-title>
          <source>Prog Cardiovasc Dis</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>395</fpage>
          <lpage>414</lpage>
          <issue>5</issue>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Froelicher</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Shetler</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ashley</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Morise AP, Detrano R, Bobbio M, Diamond     GA. Development and validation of a logistic regression-derived algorithm     for estimating the incremental probability of coronary artery disease before     and after exercise testing. J Am Coll Cardiol. 1992;20(5):1187-96.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Development and validation of a logistic regression-derived algorithm for estimating the incremental probability of coronary artery disease before and after exercise testing</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>1187</fpage>
          <lpage>96</lpage>
          <issue>5</issue>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morise</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Detrano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bobbio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Diamond</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Mark DB, Mark AH, Harrell FE, Lee KL,     Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in     coronary artery disease. Ann Intern Med. 1987;106(6):793-800.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise treadmill score for predicting prognosis in coronary artery disease</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>793</fpage>
          <lpage>800</lpage>
          <issue>6</issue>
          <volume>106</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mark</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Mark</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Harrell</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Califf</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Pryor</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Raxwal V, Shetler K, Morise A, Do D, Myers     J, Atwood JE, et al. Simple treadmill score to diagnose coronary disease.     Chest. 2001;119(6):1933-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Simple treadmill score to diagnose coronary disease</article-title>
          <source>Chest</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1933</fpage>
          <lpage>40</lpage>
          <issue>6</issue>
          <volume>119</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Raxwal</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Shetler</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Morise</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Do</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Atwood</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Do D, West JA, Morise A, Atwood E, Froelicher     V. A consensus approach to diagnosing coronary artery disease based on clinical     and exercise test data. Chest. 1997;111(6):1742-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A consensus approach to diagnosing coronary artery disease based on clinical and exercise test data</article-title>
          <source>Chest</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>1742</fpage>
          <lpage>9</lpage>
          <issue>6</issue>
          <volume>111</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Do</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Morise</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Atwood</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Froelicher</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Hubbard BL, Gibbons RJ, Lapeyre AC 3rd,     Zinsmeister AR, Clements IP. Identification of severe coronary artery disease     using simple clinical parameters. Arch Intern Med. 1992;152(2):309-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Identification of severe coronary artery disease using simple clinical parameters</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>309</fpage>
          <lpage>12</lpage>
          <issue>2</issue>
          <volume>152</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hubbard</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Gibbons</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Lapeyre 3rd</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Zinsmeister</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>IP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Morrow K, Morris CK, Froelicher VF, Hideg     A, Hunter D, Johnson E, et al. Prediction of cardiovascular death in men     undergoing noninvasive evaluation for coronary artery disease. Ann Intern     Med. 1993;118(9):689-95.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prediction of cardiovascular death in men undergoing noninvasive evaluation for coronary artery disease</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>689</fpage>
          <lpage>95</lpage>
          <issue>9</issue>
          <volume>118</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morrow</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Froelicher</surname>
              <given-names>VF</given-names>
            </name>
            <name>
              <surname>Hideg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Detrano R, Bobbio M, Olson H, Shandling     A, Ellestad MH, Alegria E, et al. Computer probability estimates of angiographic     coronary artery disease: transportability and comparison with cardiologist's     estimates. Comput Biomed Res. 1992;25(5):468-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Computer probability estimates of angiographic coronary artery disease: transportability and comparison with cardiologist's estimates</article-title>
          <source>Comput Biomed Res</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>468</fpage>
          <lpage>85</lpage>
          <issue>5</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Detrano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bobbio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shandling</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ellestad</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Alegria</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Lu ZY, Haus S. Evaluation of exercise-induced     QRS amplitude changes (Athens score) and their clinical value. J Tongji Med     Univ. 1993;13(3):177-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evaluation of exercise-induced QRS amplitude changes (Athens score) and their clinical value</article-title>
          <source>J Tongji Med Univ</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>177</fpage>
          <lpage>82</lpage>
          <issue>3</issue>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lu</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Haus</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Villella M, Villella A, Santoro L, Santoro     E, Franzosi MG, Maggioni AP, et al. Ergometric score systems after myocardial     infarction: prognostic performance of the Duke Treadmill Score, Veterans     Administration Medical Center Score, and of a novel score system, GISSI-2     Index, in a cohort of survivors of acute myocardial infarction. Am Heart     J. 2003;145(3):475-83.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ergometric score systems after myocardial infarction: prognostic performance of the Duke Treadmill Score, Veterans Administration Medical Center Score, and of a novel score system, GISSI-2 Index, in a cohort of survivors of acute myocardial infarction</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>475</fpage>
          <lpage>83</lpage>
          <issue>3</issue>
          <volume>145</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Villella</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Villella</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Santoro</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Santoro</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Franzosi</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Maggioni</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Koide Y, Yotsukura M, Yoshino H, Ishikawa     K. A new coronary artery disease index of treadmill exercise electrocardiograms     based on the step-up diagnostic method. Am J Cardiol. 2001;15;87(2):142-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A new coronary artery disease index of treadmill exercise electrocardiograms based on the step-up diagnostic method</article-title>
          <source>Am J Cardiol.</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>142</fpage>
          <lpage>7</lpage>
          <issue>2</issue>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Koide</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yotsukura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yoshino</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Hollenberg M, Budge WR, Wisneski JA,     Gertz EW. Treadmill score quantifies electrocardiographic response to exercise     and improves test accuracy and reproducibility. Circulation. 1980;61(2):276-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Treadmill score quantifies electrocardiographic response to exercise and improves test accuracy and reproducibility</article-title>
          <source>Circulation</source>
          <date>
            <year>1980</year>
          </date>
          <fpage>276</fpage>
          <lpage>85</lpage>
          <issue>2</issue>
          <volume>61</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hollenberg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Budge</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Wisneski</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Gertz</surname>
              <given-names>EW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Mark DB, Shaw L, Harrell FE Jr, Hlatky     MA, Lee KL, Bengtson JR, et al. Prognostic value of a treadmill exercise     score in outpatients with suspected coronary artery disease. N Engl J Med.     1991;325(12):849-53.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>849</fpage>
          <lpage>53</lpage>
          <issue>12</issue>
          <volume>325</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mark</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Harrell Jr</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Hlatky</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Bengtson</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Ho KT, Miller TD, Hodge DO, Bailey KR,     Gibbons RJ. Use of a simple clinical score to predict prognosis of patients     with normal or mildly abnormal resting electrocardiographic findings undergoing     evaluation for coronary artery disease. Mayo Clin Proc. 2002;77(6):515-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Use of a simple clinical score to predict prognosis of patients with normal or mildly abnormal resting electrocardiographic findings undergoing evaluation for coronary artery disease</article-title>
          <source>Mayo Clin Proc</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>515</fpage>
          <lpage>21</lpage>
          <issue>6</issue>
          <volume>77</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Hodge</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Gibbons</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Soares PR, Hueb WA, Lemos PA, Lopes N,     Martinez EE, Cesar LA, et al. Coronary revascularization (surgical or percutaneous)     decreases mortality after the first year in diabetic subjects but not in     nondiabetic subjects with multivessel disease: an analysis from the Medicine,     Angioplasty, or Surgery Study (MASS II). Circulation. 2006;114(1 Suppl):I420-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II)</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>I420</fpage>
          <lpage>4</lpage>
          <volume>114</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Soares</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Hueb</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Lemos</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Cesar</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Hueb WA, Bellotti G, Oliveira SA, Arie     S, Albuquerque CP, Jatene AD, et al. The Medicine, Angioplasty or Surgery     Study (MASS): a prospective, randomized trial of medical therapy, balloon     angioplasty or bypass surgery for single proximal left anterior descending     artery stenoses. J Am Coll Cardiol. 1995;26(7):1600-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1600</fpage>
          <lpage>5</lpage>
          <issue>7</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hueb</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Bellotti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Arie</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Albuquerque</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Jatene</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Bruce RA. Evaluation of functional capacity     and exercise tolerance of cardiac patients. Mod Concepts Cardiovasc Dis.     1956;25(4):321-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evaluation of functional capacity and exercise tolerance of cardiac patients</article-title>
          <source>Mod Concepts Cardiovasc Dis</source>
          <date>
            <year>1956</year>
          </date>
          <fpage>321</fpage>
          <lpage>6</lpage>
          <issue>4</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bruce</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Brito FS, Vilas-Boas F, Castro I, Oliveira     J&#193;, Guimar&#227;es JI, Stein R/ Sociedade Brasileira de Cardiologia.     II Diretriz sobre teste ergom&#233;trico. Arq Bras Cardiol. 2002;78(supl     2):1-18.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>II Diretriz sobre teste ergom&#233;trico</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1</fpage>
          <lpage>18</lpage>
          <volume>78</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brito</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Vilas-Boas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>J&#193;</given-names>
            </name>
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>JI</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Cox DR. Regression models and life-tables.     J R Stat Soc Ser B Metodol. 1972;34(2):187-220.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Regression models and life-tables</article-title>
          <source>J R Stat Soc Ser B Metodol</source>
          <date>
            <year>1972</year>
          </date>
          <fpage>187</fpage>
          <lpage>220</lpage>
          <issue>2</issue>
          <volume>34</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cox</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Kaplan EL, Meier P. Nonparametric estimation     from incomplete observations. Am Stat Soc. 1958;53:457-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Nonparametric estimation from incomplete observations</article-title>
          <source>Am Stat Soc</source>
          <date>
            <year>1958</year>
          </date>
          <fpage>457</fpage>
          <lpage>81</lpage>
          <volume>53</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kaplan</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Meier</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Yusuf S, Sleight P, Pogue J, Bosch J,     Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor,     ramipril, on cardiovascular events in high-risk patients: the heart outcomes     prevention evaluation study investigators. N Engl J Med. 2000;342(3):145-53.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the heart outcomes prevention evaluation study investigators</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>145</fpage>
          <lpage>53</lpage>
          <issue>3</issue>
          <volume>342</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sleight</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pogue</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bosch</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dagenais</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Fox KM. Efficacy of perindopril in reduction     of cardiovascular events among patients with stable coronary artery disease:     randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA     study). Lancet. 2003;362(9386):782-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)</article-title>
          <source>Lancet</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>782</fpage>
          <lpage>8</lpage>
          <issue>9386</issue>
          <volume>362</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fox</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Poole-Wilson PA, Lubsen J, Kirwan BA,     van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine     on mortality and cardiovascular morbidity in patients with stable angina     requiring treatment (ACTION trial): randomised controlled trial. Lancet.     2004;364(9437):849-57.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial</article-title>
          <source>Lancet</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>849</fpage>
          <lpage>57</lpage>
          <issue>9437</issue>
          <volume>364</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Poole-Wilson</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Lubsen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kirwan</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>van Dalen</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Wagener</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Danchin</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Pryor DB, Shaw L, Harrell FE Jr, Lee     KL, Hlatky MA, Mark DB, et al. Estimating the likelihood of severe coronary     artery disease. Am J Med. 1991;90(5):553-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Estimating the likelihood of severe coronary artery disease</article-title>
          <source>Am J Med</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>553</fpage>
          <lpage>62</lpage>
          <issue>5</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pryor</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Harrell Jr</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Hlatky</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Mark</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Yamada H, Do D, Morise A, Atwood JE,     Froelicher V. Review of studies using multivariable analysis of clinical     and exercise test data to predict angiographic coronary artery disease. Prog     Cardiovasc Dis. 1997;39(5):457-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Review of studies using multivariable analysis of clinical and exercise test data to predict angiographic coronary artery disease</article-title>
          <source>Prog Cardiovasc Dis</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>457</fpage>
          <lpage>81</lpage>
          <issue>5</issue>
          <volume>39</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Do</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Morise</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Atwood</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Froelicher</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Prakash M, Myers J, Froelicher VF, Marcus     R, Do D, Kalisetti D, et al. Clinical and exercise test predictors of all-cause     mortality: results from &gt; 6,000 consecutive referred male patients. Chest.     2001;120(3):1003-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical and exercise test predictors of all-cause mortality: results from &gt; 6,000 consecutive referred male patients</article-title>
          <source>Chest</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1003</fpage>
          <lpage>13</lpage>
          <issue>3</issue>
          <volume>120</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Prakash</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Froelicher</surname>
              <given-names>VF</given-names>
            </name>
            <name>
              <surname>Marcus</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Do</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kalisetti</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Kannel WB, Sorlie P, McNamara PM. Prognosis     after initial myocardial infarction: the Framingham study. Am J Cardiol.     1979;44(1):53-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognosis after initial myocardial infarction: the Framingham study</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1979</year>
          </date>
          <fpage>53</fpage>
          <lpage>9</lpage>
          <issue>1</issue>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Sorlie</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>McNamara</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Gibbons RJ. Exercise ECG testing with     and without radionuclide studies. In Wenger NK, Speroff L, Packard B, eds.     Cardiovascular health and disease in women. London: Le Jacq Communications;     1993. p. 73-80.</mixed-citation>
        <element-citation publication-type="book">
          <source>Exercise ECG testing with and without radionuclide studies.In Wenger NK, Speroff L, Packard B, eds. Cardiovascular health and disease in women</source>
          <date>
            <year>1993</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Gibbons</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Mansur AP, Armaganijan D, Amino JG, Sousa     AC, Sim&#227;o AF, Brito AX, et al./Sociedade Brasileira de Cardiologia.     Diretriz de doen&#231;a coronariana cr&#244;nica angina est&#225;vel.     Arq Bras Cardiol. 2004; 83(supl.2):7-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sociedade Brasileira de Cardiologia: Diretriz de doen&#231;a coronariana cr&#244;nica angina est&#225;vel</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>7</fpage>
          <lpage>40</lpage>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mansur</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Armaganijan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Amino</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Sousa</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Sim&#227;o</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Brito</surname>
              <given-names>AX</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Singh M, Gersh BJ, McClelland RL, Ho     KK, Willerson JT, Penny WF, et al. Clinical and angiographic predictors of     restenosis after percutaneous coronary intervention: insights from the Prevention     of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulation.     2004;109(22):2727-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial</article-title>
          <source>Circulation</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2727</fpage>
          <lpage>31</lpage>
          <issue>22</issue>
          <volume>109</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gersh</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>McClelland</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Willerson</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Penny</surname>
              <given-names>WF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Wilson PW, D'Agostino RB, Levy D, Belanger     AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using     risk factor categories. Circulation. 1998;97(18):1837-47.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prediction of coronary heart disease using risk factor categories</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1837</fpage>
          <lpage>47</lpage>
          <issue>18</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>D'Agostino</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Belanger</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Silbershatz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Poornima IG, Miller TD, Christian TF,     Hodge DO, Bailey KR, Gibbons RJ. Utility of myocardial perfusion imaging     in patients with low-risk treadmill scores. J Am Coll Cardiol. 2004;43(2):194-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Utility of myocardial perfusion imaging in patients with low-risk treadmill scores</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>194</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Poornima</surname>
              <given-names>IG</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Christian</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>Hodge</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Gibbons</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Mora S, Redberg RF, Sharrett AR, Blumenthal     RS. Enhanced risk assessment in asymptomatic individuals with exercise testing     and Framingham risk scores. Circulation. 2005;112(11):1566-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1566</fpage>
          <lpage>72</lpage>
          <issue>11</issue>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mora</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Redberg</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Sharrett</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Blumenthal</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Evaluaci&#243;n pron&#243;stica de la enfermedad coronaria estable a trav&#233;s de un nuevo score</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La necesidad de mejorar la exactitud de las pruebas de estr&#233;s, determin&#243; el desarrollo de los puntajes, cuya aplicaci&#243;n fue ampliamente reconocida. OBJETIVO: La evaluaci&#243;n pron&#243;stica del coronari&#243;pata estable a trav&#233;s de un nuevo score simplificado. M&#201;TODOS: Un nuevo score se aplic&#243; en 372 coronari&#243;patas multiarteriales y funci&#243;n ventricular preservada, el 71,8% varones, edad media de 59,5 (&#177; 9,07) a&#241;os, randomizados para angioplastia, revascularizaci&#243;n quir&#250;rgica y tratamiento cl&#237;nico, seguidos de cinco a&#241;os. Muerte cardiovascular fue el resultado primario. El infarto de miocardio no fatal, la muerte y la re-intervenci&#243;n formaron el desenlace combinado secundario. El score se bas&#243; en una ecuaci&#243;n previamente validada resultante de la suma de 1 punto a: sexo masculino, antecedentes de infarto, angina, diabetes, uso de insulina y todav&#237;a un punto por cada d&#233;cada de vida despu&#233;s de 40 a&#241;os. Prueba positiva a&#241;adida 1 punto. RESULTADOS: Hubo 36 muertes (10 en el grupo de angioplastia, 15 en el grupo de revascularizaci&#243;n y 11 en el grupo cl&#237;nico), p = 0,61. Se observ&#243; 93 eventos combinados: 37 en el grupo angioplastia, 23 en el grupo revascularizaci&#243;n y 33 en el grupo cl&#237;nico (p = 0,058). Presentaron score cl&#237;nico &gt; 5 puntos y 216 &gt; 6 puntos 247 pacientes. El valor de corte &gt; 5 o &gt; 6 puntos identific&#243; un mayor riesgo, con p = 0,015 y p = 0,012, respectivamente. La curva de sobrevida mostr&#243; una incidencia de muerte despu&#233;s de la aleatorizaci&#243;n que aquellos con score &gt; 6 puntos (p = 0,07), y una incidencia de eventos combinados diferentes entre los pacientes con score &lt; 6 y &gt; 6 puntos (p = 0,02). CONCLUSI&#211;N: El nuevo score demostr&#243; consistencia en la evaluaci&#243;n pron&#243;stica del coronari&#243;pata estable multiarterial. (Arq Bras Cardiol 2011;96(5):411-419)</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Prueba de esfuerzo</kwd>
        <kwd>enfermedad coronaria</kwd>
        <kwd>angina de pecho</kwd>
        <kwd>pron&#243;stico</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="topo-body2"/>Evaluaci&#243;n pron&#243;stica de la enfermedad coronaria estable a trav&#233;s de un nuevo score</p>
      <p>
        <bold>Fernanda Coutinho Storti; Paulo Jorge Moffa; Augusto H. Uchida; Whady Armindo Hueb; Luiz Ant&#244;nio Machado C&#233;sar; Beatriz Moreira Ayub Ferreira; Paulo Augusto de Camargo Jr; William Azem Chalela</bold>
      </p>
      <p>Instituto do Cora&#231;&#227;o - HCFMUSP - S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> La necesidad de mejorar la exactitud de las pruebas de estr&#233;s, determin&#243; el desarrollo de los puntajes, cuya aplicaci&#243;n fue ampliamente reconocida.</p>
      <p><bold>OBJETIVO:</bold> La evaluaci&#243;n pron&#243;stica del coronari&#243;pata estable a trav&#233;s de un nuevo score simplificado.</p>
      <p><bold>M&#201;TODOS:</bold> Un nuevo score se aplic&#243; en 372 coronari&#243;patas multiarteriales y funci&#243;n ventricular preservada, el 71,8% varones, edad media de 59,5 (&#177; 9,07) a&#241;os, randomizados para angioplastia, revascularizaci&#243;n quir&#250;rgica y tratamiento cl&#237;nico, seguidos de cinco a&#241;os. Muerte cardiovascular fue el resultado primario. El infarto de miocardio no fatal, la muerte y la re-intervenci&#243;n formaron el desenlace combinado secundario. El score se bas&#243; en una ecuaci&#243;n previamente validada resultante de la suma de 1 punto a: sexo masculino, antecedentes de infarto, angina, diabetes, uso de insulina y todav&#237;a un punto por cada d&#233;cada de vida despu&#233;s de 40 a&#241;os. Prueba positiva a&#241;adida 1 punto.</p>
      <p><bold>RESULTADOS:</bold> Hubo 36 muertes (10 en el grupo de angioplastia, 15 en el grupo de revascularizaci&#243;n y 11 en el grupo cl&#237;nico), p = 0,61. Se observ&#243; 93 eventos combinados: 37 en el grupo angioplastia, 23 en el grupo revascularizaci&#243;n y 33 en el grupo cl&#237;nico (p = 0,058). Presentaron score cl&#237;nico <underline>&gt;</underline> 5 puntos y 216 <underline>&gt;</underline> 6 puntos 247 pacientes. El valor de corte <underline>&gt;</underline> 5 o <underline>&gt;</underline> 6 puntos identific&#243; un mayor riesgo, con p = 0,015 y p = 0,012, respectivamente. La curva de sobrevida mostr&#243; una incidencia de muerte despu&#233;s de la aleatorizaci&#243;n que aquellos con score <underline>&gt;</underline> 6 puntos (p = 0,07), y una incidencia de eventos combinados diferentes entre los pacientes con score &lt; 6 y <underline>&gt;</underline> 6 puntos (p = 0,02).</p>
      <p><bold>CONCLUSI&#211;N:</bold> El nuevo score demostr&#243; consistencia en la evaluaci&#243;n pron&#243;stica del coronari&#243;pata estable multiarterial. (Arq Bras Cardiol 2011;96(5):411-419)</p>
      <p><bold>Palabras clave:</bold> Prueba de esfuerzo, enfermedad coronaria, angina de pecho, pron&#243;stico.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Incluso con los avances en la medicina, la prueba de esfuerzo (PE), con su bajo coste, la seguridad y la f&#225;cil aplicabilidad se la recomienda la Directriz Americana<sup>1</sup> como el primer procedimiento que se realiza en pacientes con enfermedad arterial coronaria (EAC). De este modo, maximizar la informaci&#243;n obtenida en la PE es de suma importancia y la necesidad de mejorar su precisi&#243;n, determin&#243; el desarrollo de los scores, ampliamente reconocido en la literatura cient&#237;fica<sup>2-9</sup>. </p>
      <p>Para un enfoque m&#225;s did&#225;ctico de la EAC, dichos scores se clasificaron en: pre prueba, pos prueba, simplificados, multivariados, diagn&#243;sticos o pron&#243;sticos. En un score pre prueba, solamente se analizan las variables cl&#237;nicas, con la incorporaci&#243;n de los par&#225;metros de la PE se define un score pos prueba<sup>6</sup>.</p>
      <p>Entre los scores pre-prueba tenemos: Diamond-Forrester<sup>2</sup>, Morise y Jalisi<sup>3</sup>, Froelicher et al<sup>4</sup> y Hubbard et al<sup>10</sup>, entre otros. Este an&#225;lisis probabil&#237;stico es recomendado por la Directriz Americana sobre<sup>1</sup> PE. </p>
      <p>Entre los principales scores pos prueba est&#225;n: Mark et al<sup>7</sup>, Raxwal et al<sup>8</sup>, Morrow et al<sup>11</sup>, Froelicher et al<sup>4</sup>, Morise et al<sup>3</sup>, Do et al<sup>9</sup>, Morise et al<sup>6</sup>, Detrano et al<sup>12</sup>, Lu et al<sup>13</sup>, Villella et al (GISSI 2)<sup>14</sup>, Koide et al<sup>5</sup>, Hollenberg et al<sup>16</sup>.</p>
      <p>Los scores basados en las ecuaciones multivariadas tienen f&#243;rmulas complejas, de las cuales se derivan scores simplificados cuyos c&#225;lculos implican la simple suma de puntos. </p>
      <p>Los scores de diagn&#243;stico est&#225;n destinados para estimar la probabilidad de EAC, pudiendo tener un valor pron&#243;stico cuando se realiza la estimaci&#243;n de la enfermedad severa (un est&#225;ndar triarterial o lesi&#243;n de tronco de coronaria izquierda). Scores pron&#243;sticos son muy adecuadas para la evaluaci&#243;n de riesgo, especialmente de muerte cardiovascular o infarto no-fatal.</p>
      <p>El score pron&#243;stico que m&#225;s se utiliza es el de Mark et al (Duke)<sup>17</sup>, y aunque es ampliamente validado, no clasifica a los pacientes adecuadamente como asintom&#225;ticos, adultos mayores, en la pos-revascularizaci&#243;n del miocardio (reciente) y el pos-infarto del miocardio reciente. Por otra parte, se compone exclusivamente de los datos de la PE, sus resultados y su clasificaci&#243;n en categor&#237;as de riesgo son complejos y de dif&#237;cil memorizaci&#243;n. </p>
      <p>Un score cl&#237;nico simplificado fue idealizado por Hubbard et al<sup>10</sup> con fines de diagn&#243;stico, y valid&#225;ndose posteriormente<sup>18</sup> para el an&#225;lisis pron&#243;stico de la EAC. Sin embargo, este resultado no incluye una prueba de isquemia en su composici&#243;n, ya que impacta en el pron&#243;stico del portador de coronariopat&#237;a.</p>
      <p>Con el objetivo de proporcionar una estratificaci&#243;n de riesgo m&#225;s completa y objetiva del coronari&#243;pata estable, propusimos un nuevo score pos-prueba que inclu&#237;a el resultado de la PE con los par&#225;metros del score de Hubbard et al<sup>10</sup>.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>El estudio se bas&#243; en un an&#225;lisis retrospectivo de los datos recogidos prospectivamente del estudio (MASS-II) Hueb et al<sup>19</sup> con 05 a&#241;os de seguimiento. MASS est&#225; referida a la sigla de Medicine, Angioplasty or Surgery Study, cuyo objetivo era evaluar rand&#243;micamente el tratamiento de pacientes con coronariopat&#237;a estable multiarterial y funci&#243;n ventricular preservada. El modelo del estudio, criterios de selecci&#243;n y procedimientos de randomizaci&#243;n se publicaron<sup>20</sup> previamente. El estudio fue aprobado por el comit&#233; cient&#237;fico y de &#233;tica y todos firmaron un formulario de consentimiento libre. Todas las PE se realizaron en una cinta rodante Fukuda Denshi STAR ML-8000, con 15 derivaciones simult&#225;neas y protocolo de Bruce<sup>21</sup>.</p>
      <p>Inicialmente, se seleccionaron 611 pacientes, 18 de ellos no se sometieron a PE por razones sociales, 58 tuvieron la PE considerada como no conclusiva (presencia de bloqueo de rama izquierda, fibrilaci&#243;n auricular e hipertrofia ventricular izquierda) y en 163 pacientes, el examen se consider&#243; ineficaz, por no alcanzar la frecuencia card&#237;aca subm&#225;xima. </p>
      <p>As&#237;, la muestra final de este estudio incluy&#243; a 372 pacientes, todos con confirmaci&#243;n cinecoronariogr&#225;fica de enfermedad bi o triarterial y funci&#243;n ventricular izquierda preservada, siendo 267 hombres (71,8%), con una edad media de 59.5 (&#177; 9,07) a&#241;os, distribuidos en tres grupos: angioplastia coronaria transluminal (ACT) 34,4%, la cirug&#237;a de revascularizaci&#243;n mioc&#225;rdica (CRM) y el tratamiento cl&#237;nico (TC) 30,6%.</p>
      <p>El delineamiento del estudio permiti&#243; a los pacientes una translocaci&#243;n entre los diferentes grupos de tratamiento, basados en la ocurrencia de s&#237;ntomas en cualquier momento del estudio. No hubo diferencias en los tipos de medicamentos entre los tres grupos. </p>
      <p>Los criterios de inclusi&#243;n fueron:</p>
      <p>1. Angina estable.</p>
      <p>2. Fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo (FEVI) considerada normal, evaluada por el ecocardiograma doppler a trav&#233;s del m&#233;todo &#225;rea-longitud.</p>
      <p>3. Confirmaci&#243;n angiogr&#225;fica de la EAC bi o triartrial, con la documentaci&#243;n de la obstrucci&#243;n luminal de por lo menos el 70%, considerando s&#243;lo las ramas coronarias principales.</p>
      <p>Criterios de no-inclusi&#243;n:</p>
      <p>1. Valvulopatias.</p>
      <p>2. Aneurisma ventricular izquierdo.</p>
      <p>3. La disfunci&#243;n ventricular izquierda.</p>
      <p>4. Accidente vascular encef&#225;lico previo.</p>
      <p>5. Limitaci&#243;n de an&#225;lisis morfol&#243;gico para la definici&#243;n de la isquemia mioc&#225;rdica en el electrocardiograma: El s&#237;ndrome de pre-excitaci&#243;n ventricular, bloqueo de rama izquierda y otros trastornos de la conducci&#243;n intraventricular, sobrecarga ventricular izquierda, estimulaci&#243;n cardiaca artificial, etc.</p>
      <p>6. La discapacidad f&#237;sica de ning&#250;n tipo.</p>
      <p>
        <bold>Score cl&#237;nico simplificado o score de Hubbard</bold>
      </p>
      <p>El score de Hubbard et al<sup>10</sup> fue validado retrospectivamente en una poblaci&#243;n consecutiva y sintom&#225;tica a la investigaci&#243;n de coronariopat&#237;a, a trav&#233;s de centellograf&#237;a mioc&#225;rdica y cinecoronariograf&#237;a dentro de hasta 6 meses. Mediante los an&#225;lisis de regresi&#243;n log&#237;stica, se seleccionaron cinco variables que componen un score de 5 puntos que proporcionaba estimaciones de coronariopat&#237;a severa, lo que demostraba que la severidad de la enfermedad aumenta en funci&#243;n del puntaje.</p>
      <p>Dicho score es resultado de la suma de 1 punto por cada par&#225;metro: sexo masculino, antecedentes de infarto de miocardio y/u ondas Q en el electrocardiograma, la angina t&#237;pica, diabetes, uso de insulina y todav&#237;a punt&#250;a seg&#250;n el grupo de edad. Hasta los 39 a&#241;os no de adiciona puntos, de los 40 a los 49 a&#241;os se suma 1 punto, de los 50 a los 59 a&#241;os, 2 puntos, de los 60 a los 69 a&#241;os, 3 puntos, de los 70 a los 79 a&#241;os, 4 puntos y <underline>&gt;</underline> 80 a&#241;os, 5 puntos. </p>
      <p>El score var&#237;a desde cero a 10 puntos, la estimaci&#243;n de la probabilidad de coronariopat&#237;a en 3 grupos: alta (&gt; 5 puntos), intermediaria (igual a 5 puntos) y baja (&lt; 5 puntos).</p>
      <p>
        <bold>Desarrollo del nuevo score</bold>
      </p>
      <p>El nuevo score se estructur&#243; sobre la base de la sumatoria simple de las variables del score de Hubbard et al<sup>10</sup>, tambi&#233;n incorpor&#243; el resultado de la PE. Cuando la PE resultaba positiva, se adicion&#243; 1 punto. La PE negativa no determin&#243; puntaje adicional. As&#237;, el puntaje total del nuevo score vari&#243; de 0 a 11 puntos conforme se muestra en la <xref ref-type="table" rid="t1-body2">Tabla 1</xref>. El valor de corte considerado para alto riesgo de eventos y muerte fue de 6 puntos, tras un an&#225;lisis de la curva de sobrevida.</p>
      <table-wrap id="t1-body2">
        <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gt01-es.jpg"/></table-wrap>
      <p>Se consider&#243; una prueba positiva la presencia de la depresi&#243;n del segmento ST <underline>&gt;</underline> 1 mm, de morfolog&#237;a horizontal o hacia abajo, durante o despu&#233;s del ejercicio, y la magnitud del desnivel que se midi&#243; a 80 ms del punto J; o la presencia de elevaci&#243;n del segmento ST <underline>&gt;</underline> 1,0 mm en derivaciones sin ondas Q patol&#243;gicas, siguiendo las recomendaciones de las directrices sobre la PE<sup>1,22</sup>.</p>
      <p>El resultado positivo fue considerado como la prueba documental de la isquemia mioc&#225;rdica, adicionado un punto en el nuevo score pron&#243;stico. El resultado negativo se defini&#243; como la ausencia de documentaci&#243;n de isquemia mioc&#225;rdica y sin valor pron&#243;stico adicional en el score.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>La asociaci&#243;n entre el nuevo score y cada uno de los resultados fue analizada por la regresi&#243;n de Cox<sup>23</sup>, incluso para la identificaci&#243;n de subgrupos de alto riesgo. La curva de supervivencia cardiovascular se gener&#243; seg&#250;n la prueba con el m&#233;todo de Kaplan-Meier<sup>24</sup> y la prueba Log-Rank aplicado para comparar estas curvas de supervivencia. Para todos los an&#225;lisis de una p &lt; 0,05 fue considerada estad&#237;sticamente significativa.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>De los 372 pacientes estudiados, 156 pacientes ten&#237;an antecedentes de infarto de miocardio, al menos 334 ten&#237;an angina clase funcional II, 137 (36,8%) eran diab&#233;ticos, siendo 16 (0,11%) usuarios regulares de insulina. </p>
      <p>Durante el per&#237;odo total de seguimiento, hubo 29 episodios de infarto de miocardio no fatal, y 11 en el grupo con ATC, 6 en el grupo de RM y 12 en el grupo TC, esta diferencia se observ&#243; entre los grupos y no fue significativa (p = 0,21).</p>
      <p>En cuanto a la necesidad de RM despu&#233;s de la aleatorizaci&#243;n, hubo 06 casos en el grupo ATC, 2 casos en el grupo RM y 16 casos en el grupo TC, esta diferencia entre los grupos fue considerada estad&#237;sticamente significativa (p = 0,001).</p>
      <p>La necesidad de ATC despu&#233;s de la aleatorizaci&#243;n, se observ&#243; en 18 casos en el grupo ATC, 3 casos en el grupo RM y en 04 casos en el grupo TC, y esta diferencia entre los grupos fue considerada significativa (p = 0,001).</p>
      <p>Observamos 36 muertes durante el seguimiento, 10 en el grupo de ATC, 15 en el grupo RM y 11 casos en el grupo TC (p = 0,61). La incidencia de muerte tras la randomizaci&#243;n se observ&#243; en 10 pacientes con score &lt; 6 puntos y en 26 pacientes con score &gt; 6 puntos (p = 0,07).</p>
      <p>El total de eventos combinados fue de 93, con la siguiente distribuci&#243;n entre los grupos: 37 en el grupo de ATC, 23 en el grupo RM y 33 en el grupo TC, con diferencia marginalmente significativa (p = 0,058). La incidencia de eventos combinados despu&#233;s de la randomizaci&#243;n se observ&#243; en 34 pacientes con score &lt; 6 puntos y en 59 pacientes con score <underline>&gt;</underline> 6 puntos (p = 0,22).</p>
      <p>Al evaluar la edad para los diferentes grupos, no hubo diferencia significativa (p = 0,73), con edad media de 59,75 &#177; 9,5 a&#241;os para el grupo ATC (127 pacientes), 59,97 &#177; 8,4 a&#241;os para el grupo RM (130 pacientes), 59,08 &#177; 9,3 a&#241;os para el grupo TC (115 pacientes).</p>
      <p>En cuanto al sexo, un score inferior a 06 puntos se observ&#243; en 97 hombres y 59 mujeres. Score <underline>&gt;</underline> 06 puntos se observ&#243; en 169 hombres y en 47 mujeres.</p>
      <p>La necesidad de RM tras la randomizaci&#243;n se observ&#243; en 8 pacientes con score &lt; 6 puntos y en 16 pacientes con score <underline>&gt;</underline> 6 puntos (p = 0,37).</p>
      <p>La necesidad de ATC tras la randomizaci&#243;n se observ&#243; en 12 pacientes con score &lt; 6 puntos y en 13 pacientes con score <underline>&gt;</underline> 6 puntos (p = 0,52).</p>
      <p>El an&#225;lisis de curva de la supervivencia que demostr&#243; que hubo diferencia marginalmente significativa en la incidencia de eventos combinados para los pacientes con un score de Hubbard &lt; 5 o <underline>&gt;</underline> 5 puntos (p = 0,062), (<xref ref-type="fig" rid="esa10f1-body2">Figura 1</xref>).</p>
      <p content-type="asset">
        <fig id="esa10f1-body2">
          <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf01-es.jpg"/></fig>
      </p>
      <p>Cuando se evalu&#243; la incidencia de eventos combinados para el nuevo score, hubo diferencia estad&#237;sticamente significativa (p = 0,02) entre los pacientes con score &lt; 6 y <underline>&gt;</underline> 6 puntos, como muestran las respectivas curvas comparativas de sobrevida de la <xref ref-type="fig" rid="esa10f2-body2">Figura 2</xref>. </p>
      <p content-type="asset">
        <fig id="esa10f2-body2">
          <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf02-es.jpg"/></fig>
      </p>
      <p>La incidencia de muerte cardiovascular fue mayor en los pacientes con score <underline>&gt;</underline> 5 puntos por el score de Hubbard (p = 0,015), <xref ref-type="fig" rid="esa10f3-body2">Figura 3</xref>. La diferencia en la incidencia de muerte fue m&#225;s significante entre los pacientes con score &lt; 6 e <underline>&gt;</underline> 6 puntos, con p = 0,004, <xref ref-type="fig" rid="esa10f4-body2">Figura 4</xref>.</p>
      <p content-type="asset">
        <fig id="esa10f3-body2">
          <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf03-es.jpg"/></fig>
      </p>
      <p content-type="asset">
        <fig id="esa10f4-body2">
          <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf04-es.jpg"/></fig>
      </p>
      <p>Al comparar los dos scores, se observ&#243; que 31 pacientes fueron clasificados como pacientes con alto riesgo por el score de Hubbard, pero considerados como de bajo riesgo por el nuevo score. Ning&#250;n de los individuos de bajo riesgo por el score de Hubbard se clasific&#243; como de alto riesgo en el nuevo score, seg&#250;n ilustra la <xref ref-type="table" rid="t2-body2">Tabla 2</xref>. La diferencia de la clasificaci&#243;n de riesgo entre los scores fue considerada estad&#237;sticamente significante (p = 0,001). Del total de las personas analizados, 247 (66,4%) presentaron score de Hubbard <underline>&gt;</underline> 5 puntos y 216 (58%) <underline>&gt;</underline> 6 puntos, como demuestra la <xref ref-type="table" rid="t2-body2">Tabla 2</xref>. El valor de corte <underline>&gt;</underline> 5 o <underline>&gt;</underline> 6 puntos identific&#243; a individuos de mayor riesgo de muerte, con p = 0,015 y p = 0,004, respectivamente.</p>
      <table-wrap id="t2-body2">
        <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gt02-es.jpg"/></table-wrap>
      <p>En cuanto al resultado primario, el an&#225;lisis de la curva de supervivencia no mostr&#243; diferencias entre los tres grupos de tratamiento, <xref ref-type="fig" rid="esa10f5-body2">Figura 5</xref>.</p>
      <p content-type="asset">
        <fig id="esa10f5-body2">
          <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf05-es.jpg"/></fig>
      </p>
      <p>En cuanto a la incidencia de muertes y scores de Hubbard <underline>&gt;</underline> 5, hubo 15 muertes en el grupo con ATC, 12 en el grupo RM y 10 en el grupo (p = 0,59), mientras que con score &lt; 5 puntos, observamos 1 &#243;bito en el grupo ATC, 5 en el grupo RM y 3 en el grupo TC (p = 0,176). </p>
      <p>En cuanto a la incidencia de muertes y nuevo score <underline>&gt;</underline> 6, se observaron 11 muertes en el grupo ATC, 7 en el grupo RM y 6 en el grupo TC, (p = 0,4). En la presencia de nuevo score &lt; 6 puntos evidenciaron 1 muerte en el grupo ATC, 6 en el grupo RM y 3 en el grupo TC (p = 0,163). </p>
      <p>En cuanto a la ocurrencia de eventos combinados en los pacientes con scores de Hubbard <underline>&gt;</underline> 5 puntos, hubo 33 eventos en el grupo ATC, 13 en el grupo RM y 23 en el grupo TC, con una incidencia de eventos significantemente reducida en el grupo RM (p &lt; 0,001). El an&#225;lisis de la incidencia de eventos combinados en los pacientes con score de Hubbard &lt; 5 puntos, mostr&#243; 1 evento en el grupo ATC, 5 eventos en el grupo RM y 3 en el grupo TC (p = 0,24).</p>
      <p>Al analizar la incidencia de eventos combinados en pacientes con score <underline>&gt;</underline> 6 puntos, se observaron 24 eventos en el grupo ATC, 8 en el grupo RM y 12 en el grupo TC (p = 0,001). En los pacientes con score &lt; 6 puntos observamos 9 eventos en el grupo ATC, 5 en el grupo RM y 9 en el grupo TC (p = 0,334).</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La evaluaci&#243;n pron&#243;stica es un componente crucial de la evaluaci&#243;n cl&#237;nica de la EAC. Aunque los pacientes con angina estable presenten baja mortalidad<sup>25-27</sup>, el riesgo de infarto de miocardio, la necesidad de intervenciones y los s&#237;ntomas impactan la evoluci&#243;n cl&#237;nica de manera representativa. </p>
      <p>Varias scores desarrollados para la estratificaci&#243;n de EAC adopt&#225;ndose par&#225;metros cl&#237;nicos y del PE o combinados<sup>28,29</sup>. No obstante, los scores pron&#243;stico en pacientes con angina estable son raros<sup>30</sup>.</p>
      <p>La propuesta de este estudio fue desarrollar un &#237;ndice para la estratificaci&#243;n de riesgo del coronari&#243;pata multiarterial, a trav&#233;s de un m&#233;todo sencillo y asequible, en contraste con la amplia gama de procedimientos de alto costo disponibles.</p>
      <p>En nuestra casu&#237;stica, la edad media de 59,5 a&#241;os, determin&#243; un mayor valor inicial del score. La muestra estuvo representada por individuos con un rango de edad m&#225;s grande, as&#237; que con un perfil de riesgo m&#225;s alto. El predominio masculino en nuestra muestra estudiada no impact&#243; la interpretaci&#243;n de los resultados debido a la documentaci&#243;n de EAC multiarterial en ambos sexos.</p>
      <p>La mayor&#237;a de los hombres (63,29%) present&#243; score <underline>&gt;</underline> 6 puntos, mientras que en la mayor&#237;a de las mujeres se observ&#243; un score &lt; 6 puntos. El puntaje m&#225;s alto para los hombres puede estar relacionada con el hecho de que el sexo masculino ya define un puntaje adicional. Adem&#225;s de esto, infarto de miocardio es m&#225;s com&#250;n en varones, pero las mujeres presentan un pron&#243;stico peor, debido a la mayor tasa de defunci&#243;n y re-infarto<sup>31</sup>. En cuanto al dolor precordial, aunque ella sea m&#225;s frecuente en las mujeres, la prevalencia de EAC significante es menor, determinando un valor predictivo menor para las pruebas no invasivas<sup>32,33</sup>.</p>
      <p>El an&#225;lisis pron&#243;stico no tuvo en cuenta la diferencia entre los est&#225;ndares angiogr&#225;ficos bi o triarteriales debido a un bajo n&#250;mero de desenlaces en el per&#237;odo de seguimiento.</p>
      <p>La tasa de muerte (10,33%) en nuestro estudio fue mayor que la mortalidad global de los pacientes con angina estable, que es alrededor del 1% al a&#241;o seg&#250;n los datos de la directriz sobre angina estable<sup>33</sup>. Esto puede ser explicado por la presencia de un mayor n&#250;mero de pacientes de alto riesgo en nuestro estudio, con mayor prevalencia de multiarteriales y de diab&#233;ticos, a pesar de la funci&#243;n ventricular izquierda preservada.</p>
      <p>La incidencia de eventos combinados y la necesidad de reintervenci&#243;n con angioplastia despu&#233;s de la aleatorizaci&#243;n fueron mayores en el grupo ATC. Probablemente, esto se relaciona con una mayor tasa de reestenosis, ya que una parte representativa de nuestra muestra tiene diabetes. Las mayores tasas de reestenosis se encuentran com&#250;nmente en diab&#233;ticos<sup>34</sup>. </p>
      <p>La alta tasa de diabetes (36,8%) tambi&#233;n determin&#243; un mayor puntaje inicial en el score. Compatible con el hecho de que los pacientes con diabetes tienen una mayor incidencia de coronariopat&#237;a severa. Es bien sabido que la diabetes es un factor de riesgo mayor para eventos coron&#225;rios<sup>35</sup>. La diabetes tipo 2 es de particular importancia, ya que, es m&#225;s com&#250;n y ocurre frecuentemente en adultos mayores, cuando m&#250;ltiples factores de riesgo coexisten. </p>
      <p>Con respecto a la PE, los diab&#233;ticos representan un grupo particularizado: hay una mayor incidencia de hipertensi&#243;n, enfermedad vascular perif&#233;rica, neuropat&#237;a perif&#233;rica, la obesidad y la menor capacidad funcional. Por otra parte, est&#225;n m&#225;s expuestos al uso de drogas que limitan la frecuencia card&#237;aca. Por lo tanto, cuando los factores de riesgo coexisten, hay limitaciones a la realizaci&#243;n que se alcance un bajo riesgo en el score de Duke. Adem&#225;s, el nivel de trabajo realizado no puede ser suficiente para la documentaci&#243;n de isquemia mioc&#225;rdica, incluso con cualquier EAC significativa.</p>
      <p>El score de Hubbard fue seleccionado inicialmente para componer el nuevo score, ya que, contiene variables de f&#225;cil evaluaci&#243;n. El n&#250;mero de variables es peque&#241;o, el sumatorio de puntos es simplificado y de f&#225;cil interpretaci&#243;n, tiene correlaci&#243;n lineal entre el resultado y el pron&#243;stico. Adem&#225;s de esto, puede identificar a individuos de alto riesgo, aun cuando clasificados en bajo riesgo por el score de Duke<sup>36</sup>. Sin embargo, &#233;l tiene limitaciones, como el an&#225;lisis exclusivo de variables cl&#237;nicos, sin considerar una prueba documental de isquemia mioc&#225;rdica que comprobadamente suministra informaci&#243;n pron&#243;stica adicional<sup>37</sup>. </p>
      <p>Mediante la adici&#243;n de esta variable en el an&#225;lisis, 31 pacientes fueron clasificados como de bajo riesgo por el nuevo score, porque ten&#237;an una prueba ergom&#233;trica negativa. Por lo tanto, el score de Hubbard puede haber sobreestimado el grupo de mayor riesgo en la poblaci&#243;n estudiada. </p>
      <p>En la PE, aunque otras variables como la capacidad funcional, las arritmias, las respuestas inotr&#243;pica y cronotr&#243;pica, sea consideren de mayor valor predictivo que la depresi&#243;n del segmento ST, hay un vicio de interpretaci&#243;n de los varios estudios. No se consider&#243; que en la pr&#225;ctica cl&#237;nica un PE positivo acaba por implicar en la indicaci&#243;n de estudio cineangiocoronariogr&#225;fico y, consecuentemente, de tratamiento farmacol&#243;gico o procedimientos de revascularizaci&#243;n mioc&#225;rdica (quir&#250;rgica o percut&#225;nea). Tales intervenciones terap&#233;uticas determinan una alteraci&#243;n en la evoluci&#243;n natural de la enfermedad coronaria que afecta el valor pron&#243;stico del marcador electrocardiogr&#225;fico de isquemia mioc&#225;rdica.</p>
      <p>El an&#225;lisis pron&#243;stica del nuevo score no incorpor&#243; estas inn&#250;meras variables espec&#237;ficas de la PE, adoptando s&#243;lo la presencia de la documentaci&#243;n electrocardiogr&#225;fica de isquemia mioc&#225;rdica, porque el objetivo era aplicar de forma pr&#225;ctica, f&#225;cil de recordar e interpretar, por lo que es m&#225;s ampliamente aceptado tanto por el cl&#237;nico como por el especialista.</p>
      <p>Con el uso de scores pron&#243;sticos simplificados aplicados en asociaci&#243;n a la PE podemos estratificar con m&#225;s precisi&#243;n el coronari&#243;pata estable, reduciendo la tasa de solicitud de procedimientos de alta complejidad.</p>
      <p>Scores mejoran la precisi&#243;n pron&#243;stica del PE, reducen sesgos de interpretaci&#243;n y organizar las informaciones cl&#237;nicas diversas, determinando una reducci&#243;n en la subjetividad y en la variabilidad de la estratificaci&#243;n de riesgo. En particular, el score propuesto por este estudio demostr&#243; su valor pron&#243;stico de una manera integral a trav&#233;s de una sistem&#225;tica simple y organizada.</p>
      <p>
        <bold>Conclusiones</bold>
      </p>
      <p>Este nuevo score es un m&#233;todo objetivo y sencillo para la estratificaci&#243;n del riesgo de coronaria estable.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuve fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Fernanda Coutinho Storti, por InCor - HCFMUSP.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">New prognostic score for stable coronary disease evaluation</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: The need to improve the exercise testing accuracy, pushed the development of scores, whose applicability was already broadly recognized. OBJECTIVE: Prognostic evaluation of stable coronary disease through a new simplified score. METHODS: A new score was applied in 372 multivessel coronary patients with preserved ventricular function, 71.8% male, age: 59.5 (&#177; 9.07) years old, randomized to medical treatment, surgery (CABG) or angioplasty (PTCA), with 5 years of follow-up. Cardiovascular death was considered the primary endpoint. Non-fatal myocardial infarction, death and re-intervention were considered for a combined secondary endpoint. The score was based on an equation previously validated, resulting from a sum of one point for: male gender, infarction history, angina, diabetes, insulin use and one point for each decade of life after 40 years old. Positive exercise testing summed one additional point. RESULTS: Thirty six deaths was observed (10 in group PTCA, 15 in CABG and 11 in the clinical group), p = 0.61. We observed 93 combined events: 37 in PTCA group, 23 in CABG and 33 in the clinical group (p = 0.058). 247 patients presented clinical score &gt; 5 points and 216 &gt; 6 points. The cutoff point &gt; 5 or &gt; 6 points identified higher risk, p = 0.015 and p = 0.012, respectively. The survival curve showed a different death incidence after the randomization when score reached 06 points or more (p = 0.07), and a distinct incidence of combined events between the patients with score &lt; 6 and &gt; 6 points (p = 0.02). CONCLUSION: The new score was consistent for multiarterial stable coronary disease risk stratification.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Exercise test</kwd>
        <kwd>coronary disease</kwd>
        <kwd>angina pectoris</kwd>
        <kwd>prognosis</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p><undefined id="title-body3"/>New prognostic score for stable coronary disease evaluation</p>
      <p>
        <bold>Fernanda Coutinho Storti; Paulo Jorge Moffa; Augusto H. Uchida; Whady Armindo Hueb; Luiz Ant&#244;nio Machado C&#233;sar; Beatriz Moreira Ayub Ferreira; Paulo Augusto de Camargo Jr; William Azem Chalela</bold>
      </p>
      <p> Instituto do Cora&#231;&#227;o - HCFMUSP - S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND: </bold>The need to improve the exercise testing accuracy, pushed the development of scores, whose applicability was already broadly recognized.</p>
      <p><bold>OBJECTIVE: </bold>Prognostic evaluation of stable coronary disease through a new simplified score.</p>
      <p><bold> METHODS: </bold>A new score was applied in 372 multivessel coronary patients with preserved ventricular function, 71.8% male, age: 59.5 (&#177; 9.07) years old, randomized to medical treatment, surgery (CABG) or angioplasty (PTCA), with 5 years of follow-up. Cardiovascular death was considered the primary endpoint. Non-fatal myocardial infarction, death and re-intervention were considered for a combined secondary endpoint. The score was based on an equation previously validated, resulting from a sum of one point for: male gender, infarction history, angina, diabetes, insulin use and one point for each decade of life after 40 years old. Positive exercise testing summed one additional point.</p>
      <p><bold> RESULTS: </bold>Thirty six deaths was observed (10 in group PTCA, 15 in CABG and 11 in the clinical group), p = 0.61. We observed 93 combined events: 37 in PTCA group, 23 in CABG and 33 in the clinical group (p = 0.058). 247 patients presented clinical score <underline>&gt;</underline> 5 points and 216 <underline>&gt;</underline> 6 points. The cutoff point <underline>&gt;</underline> 5 or <underline>&gt;</underline> 6 points identified higher risk, p = 0.015 and p = 0.012, respectively. The survival curve showed a different death incidence after the randomization when score reached 06 points or more (p = 0.07), and a distinct incidence of combined events between the patients with score &lt; 6 and <underline>&gt;</underline> 6 points (p = 0.02).</p>
      <p><bold> CONCLUSION: </bold>The new score was consistent for multiarterial stable coronary disease risk stratification.</p>
      <p><bold>Keywords: </bold>Exercise test; coronary disease; angina <italic>pectoris</italic>; prognosis.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Even with advances in medicine, exercise testing (ET) with its low cost, security and easy applicability is recommended by the American guideline<sup>1</sup> as the first procedure to be performed in patients with coronary artery disease (CAD). Thus, maximizing the information obtained in the ET is of paramount importance and the need to improve its accuracy, determined the development of scores, widely recognized in the scientific literature<sup>2-9</sup>. </p>
      <p>For a more didactic approach of CAD, these scores were classified as: pretest, posttest, simplified, multivariate, diagnostic or prognostic. In a pre-test score, only clinical variables are analyzed, incorporating parameters of ET is defined as a post-test score<sup>6</sup>. </p>
      <p>The pre-test scores include: Diamond-Forrester<sup>2</sup>, Morise and Jalisi<sup>3</sup>, Froelicher et al<sup>4</sup> and Hubbard et al<sup>10</sup>, among others. This preliminary probabilistic analysis is recommended by the American guideline<sup>1</sup> on ET. </p>
      <p>The major post-test scores include: Mark et al<sup>7</sup>, Raxwal et al<sup>8</sup>, Morrow et al<sup>11</sup>, Froelicher et al<sup>4</sup>, Morise et al<sup>3</sup>, Do et al<sup>9</sup>, Morise et al<sup>6</sup>, Detrano et al<sup>12</sup>, Lu et al<sup>13</sup>, Villella et al (GISSI 2)<sup>14</sup>, Koide et al<sup>15</sup>, Hollenberg et al<sup>16</sup>.</p>
      <p>Scores based on multivariate equations have complex formulas, which derive simplified scores whose calculations involve the simple sum of points. </p>
      <p>Diagnostic scores are intended to estimate the probability of CAD and may have predictive value when performing the estimation of severe disease (triple vessel or pattern or left coronary artery lesion). Prognostic scores are well suited for risk assessment, especially of cardiovascular death or nonfatal myocardial infarction.</p>
      <p>The prognostic score most widely used is the one by Mark et al (Duke)<sup>17</sup>, and although it is widely validated, it does not sort properly asymptomatic, elderly patients, patients after coronary artery bypass surgery (recent) and recent post-myocardial infarction. Moreover, it is composed exclusively of ET data, its results and classification into risk categories are complex and difficult to memorize. </p>
      <p>A simplified clinical scoring system was devised by Hubbard et al<sup>10</sup> with diagnostic purposes, and subsequently validated<sup>18</sup> for prognostic analysis of CAD. However, this score does not include documentary evidence of ischemia in its composition, since it impacts the prognosis of patients with coronary artery disease.</p>
      <p>Aiming to provide a more complete and objective risk stratification of patients with stable coronary artery disease, we propose a new post-test score, which includes the result of ET with the score parameters of Hubbard et al<sup>10</sup>. </p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>The study was based on a retrospective analysis of data prospectively collected from the study (MASS-II) Hueb et al<sup>19</sup> with 05 years of follow up. MASS refers to the initials of Medicine, Angioplasty or Surgery Study, whose aim was to make a random evaluation of the treatment of patients with stable multivessel coronary artery disease and preserved ventricular function. The study design, selection criteria and randomization procedures were previously published<sup>20</sup>. The study was approved by the scientific and ethics committee, and all the patients signed an informed consent. All ET were performed on a treadmill Fukuda Denshi STAR ML- 8000, with 15 simultaneous leads and Bruce<sup>21</sup> protocol.</p>
      <p>Initially, we selected 611 patients, of which 18 patients did not undergo ET for social reasons, 58 had an inconclusive ET (presence of left bundle branch block, atrial fibrillation and left ventricular hypertrophy) and in 163 patients, the examination was considered ineffective for failing to achieve submaximal heart rate. </p>
      <p>Thus, the final sample included 372 patients, all with coronary angiographic confirmation of double or triple vessel disease and preserved left ventricular function, with 267 men (71.8%), with a mean age of 59.5 (&#177; 9.07) years, distributed into three groups: transluminal coronary angioplasty (PTCA) 34.4%, coronary artery bypass grafting (CABG) 34.9%, and clinical treatment (CT) 30.6%.</p>
      <p>The study design allowed patients to shift between the different treatment groups based on the occurrence of symptoms at any time of the study. There was no difference in the types of drugs among the three groups. </p>
      <p>The selection criteria were:</p>
      <p>1. Stable angina.</p>
      <p>2. Normal left ventricular ejection fraction (LVEF), as assessed by Doppler echocardiography using the area length method.</p>
      <p>3. Angiographic confirmation of double or triple vessel CAD, with documentation of luminal obstruction of at least 70%, considering only the main coronary branches.</p>
      <p>Non-inclusion criteria:</p>
      <p>1. Valvular Heart Diseases.</p>
      <p>2. Left ventricular aneurysm.</p>
      <p>3. Left ventricular dysfunction.</p>
      <p>4. Previous cerebrovascular accident.</p>
      <p>5. Limitation of morphological analysis for definition of myocardial ischemia on electrocardiogram: syndrome of ventricular pre-excitation, left bundle branch block and other intraventricular conduction abnormalities, left ventricular hypertrophy, cardiac pacing, etc.</p>
      <p>6. Physical disability of any kind.</p>
      <p>
        <bold>Simplified clinical score or Hubbard score</bold>
      </p>
      <p>The score of Hubbard et al<sup>10</sup> was validated retrospectively in a consecutive and symptomatic population investigated for coronary artery disease through myocardial scintigraphy and coronary angiography within 6 months. Through logistic regression analysis, we selected five variables composing a score of 5 points that provided estimates of severe coronary artery disease, demonstrating that disease severity increases with the score.</p>
      <p>This score results from the sum of 1 point for each parameter: male gender, history of myocardial infarction and/or Q waves on ECG, typical angina, diabetes, insulin use and scores according to age. Up to 39 years, points are not added, from 40 to 49, 1 point is added, 50 to 59 years, 2 points, 60 to 69 years, 3 points, 70 to 79 years, 4 points and <underline>&gt;</underline> 80 years, 5 points. </p>
      <p>The score ranges from zero to 10 points, estimating the probability of coronary artery disease in 3 groups: high (&gt; 5 points), intermediate (equal to 5 points) and low (&lt; 5 points).</p>
      <p>
        <bold>Development of the new score</bold>
      </p>
      <p>The new score was based on the simple sum of the variables of Hubbard et al<sup>10</sup> score, also incorporating the results of the ET. When the ET was positive, 1 point was added. Negative ET did not determine additional score. Thus, the total score of the new score ranged from 0 to 11 points as illustrated in <xref ref-type="table" rid="tab01-body3">Table 1</xref>. The cutoff value for high-risk events and death was 6 points, after examining the survival curve.</p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gt01-en.jpg"/></table-wrap>
      <p>A positive test was considered the presence of ST segment depression <underline>&gt;</underline> 1 mm, horizontal or downward morphology, during or after exercise, and the magnitude of the gap was measured at 80 ms from J point; or presence of ST segment elevation <underline>&gt;</underline> 1.0 mm in leads without pathological Q waves, following the recommendations of the guidelines on ET<sup>1,22</sup>.</p>
      <p>The positive result was taken as documentary evidence of myocardial ischemia, adding a new point on the prognostic score. The negative result was defined as absence of documented myocardial ischemia and no additional prognostic value in the score.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>The association between the new score and each of the outcomes was analyzed by the Cox regression<sup>23</sup>, to identify high-risk subgroups. The cardiovascular survival curve was generated according to the Kaplan-Meier method<sup>24</sup> and the Log-Rank test was used to compare these survival curves. For all the analyses, a p &lt; 0.05 was considered statistically significant.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>Out of the 372 patients studied, 156 patients had a history of myocardial infarction, 334 had angina class II, 137 (36.8%) were diabetic, and 16 (0.11%) using regular insulin. </p>
      <p>During the total follow-up, there were 29 episodes of non-fatal myocardial infarction, of which 11 in the PCI group, 6 in the CABG group and 12 in the CT group; this difference between the groups was not significant (p = 0.21).</p>
      <p>Regarding the need for CABG after randomization, there were 06 cases in the PCI group, 2 cases in the CABG group and 16 cases in the CT group, this difference between groups was statistically significant (p = 0.001).</p>
      <p>The need for CABG after randomization, there were 18 cases in the PCI group, 03 cases in the MR group and 04 cases in the CT group, this difference between groups was statistically significant (p = 0.001).</p>
      <p>We observed 36 deaths during follow-up, 10 in the PTCA group, 15 in the CABG group and 11 cases in the CT group (p = 0.61). The death rate after randomization occurred in 10 patients with score &lt; 6 points and in 26 patients with score <underline>&gt;</underline> 6 (p = 0.07).</p>
      <p>Total combined events was 93, with the following distribution between the groups: 37 in the PTCA group, 23 in the CABG group and 33 in the CT group, with a marginally significant difference (p = 0.058). The incidence of combined events after randomization was observed in 34 patients with score &lt; 6 points and in 59 patients with score <underline>&gt;</underline> 6 (p = 0.22).</p>
      <p>When assessing age for different groups, there was no significant difference (p = 0.73), with a mean age of 59.75 &#177; 9.5 years for the PCI group (127 patients), 59.97 &#177; 8.4 years for the CABG group (130 patients), 59.08 &#177; 9.3 years for the CT group (115 patients).</p>
      <p>With regard to sex, a score below 06 points was observed in 97 men and 59 women. Score <underline>&gt;</underline> 06 points was observed in 169 men and 47 women. </p>
      <p>The need for CABG after randomization occurred in 8 patients with score &lt; 6 points and in 26 patients with score &gt; 6 (p = 0.37).</p>
      <p>The need for PTCA after randomization occurred in 12 patients with score &lt; 6 points and in 13 patients with score <underline>&gt;</underline> 6 (p = 0.52).</p>
      <p>The analysis for survival curve showed that there was a marginally significant difference in the incidence of combined events for patients with a score of Hubbard &lt; 5 or <underline>&gt;</underline> 5 points (p = 0.062) (<xref ref-type="fig" rid="fig01-body3">Figure 1</xref>).</p>
      <fig id="fig01-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf01-en.jpg"/></fig>
      <p>When we assessed the incidence of combined events for the new score, there was a statistically significant difference (p = 0.02) among patients with scores &lt; 6 and <underline>&gt;</underline> 6 points, as shown by their comparative survival curves of <xref ref-type="fig" rid="fig02-body3">Figure 2</xref>. </p>
      <fig id="fig02-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf02-en.jpg"/></fig>
      <p>The incidence of cardiovascular death was higher in patients with scores <underline>&gt;</underline> 5 points by the Hubbard's score (p = 0.015), <xref ref-type="fig" rid="fig03-body3">figure 3</xref>. The difference in the incidence of death was more significant among patients with scores &lt; 6 and <underline>&gt;</underline> 6, p = 0.004, <xref ref-type="fig" rid="fig04-body3">Figure 4</xref>.</p>
      <fig id="fig03-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf03-en.jpg"/></fig>
      <fig id="fig04-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf04-en.jpg"/></fig>
      <p>Comparing the two scores, it was observed that 31 patients were classified as high risk by the Hubbard's score, but considered with low risk by the new scoring system. No individual at low risk by the Hubbard's score was classified as high risk in the new scoring system, as illustrated in <xref ref-type="table" rid="tab02-body3">Table 2</xref>. The difference between the risk rating between scores was considered statistically significant (p = 0.001). Out of all patients analyzed, 247 (66.4%) had a score of Hubbard <underline>&gt;</underline> 5 and 216 points (58%) <underline>&gt;</underline> 6 points, as shown in <xref ref-type="table" rid="tab02-body3">Table 2</xref>. The cutoff <underline>&gt;</underline> 5 or <underline>&gt;</underline> 6 points identified individuals of higher death risk with p = 0.015 and p = 0.004, respectively.</p>
      <table-wrap id="tab02-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gt02-en.jpg"/></table-wrap>
      <p>Regarding the primary outcome, the survival curve analysis showed no difference among the three treatment groups, <xref ref-type="fig" rid="fig05-body3">Figure 5</xref>.</p>
      <fig id="fig05-body3">
        <graphic xlink:href="1678-4170-abc-96-05-0411-00046-gf05-en.jpg"/></fig>
      <p>Regarding the incidence of death and Hubbard scores <underline>&gt;</underline> 5, there were 15 deaths in the PCI group, 12 in the CABG group and 10 in the CT group (p = 0.59), while using a score &lt; 5 points, we observed 1 death in the PTCA group, 5 in the CABG group and 3 in the TC group (p = 0.176). </p>
      <p>Regarding the incidence of death and new score <underline>&gt;</underline> 5, there were 11 deaths in the PTCA group, 7 in the CABG group and 6 in the CT group (p = 0.4), while using the new score &lt; 6 points, we observed 1 death in the PTCA group, 6 in the CABG group and 3 in the TC group (p = 0.163). </p>
      <p>As for the combined events in patients with Hubbard scores <underline>&gt;</underline> 5 points, there were 33 events in the PTCA group, 13 in the CABG group and 23 in the CT group, with a significantly reduced incidence of events in the CABG group (p &lt; 0.001). Analysis of combined events in the patients with Hubbard score &lt; 5 points showed 1 event in the PTCA group, 5 events in the CABG group and 3 in the CT group (p = 0.24).</p>
      <p>By analyzing the incidence of combined events in patients with the new score <underline>&gt;</underline> 6, we observed 24 events in the PTCA group, 8 in the CABG group and 12 in the CT group (p = 0.001). In patients with a score &lt; 6 points, we observed 9 events in the PTCA group, 5 in the CABG group and 9 in the CT group (p = 0.334).</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>The prognostic evaluation is a crucial component of clinical evaluation of CAD. Although patients with stable angina have low mortality rate<sup>25-27</sup>, the risk of myocardial infarction, the need for interventions and the symptoms impact the clinical evolution in a representative manner. </p>
      <p>Several scores were developed for stratification of CAD adopting the clinical parameters and ET or combined parameters<sup>28,29</sup>. However, prognostic scores in patients with stable angina are scarce<sup>30</sup>.</p>
      <p>The objective of this study was to develop an index for risk stratification of stable multivessel coronary artery disease through a simple and affordable method, in contrast to the wide range of high-cost procedures available. </p>
      <p>In our series, the average age of 59.5 years determined a higher baseline score. Our sample was represented by individuals with a higher age range, therefore with a higher risk profile. The male predominance in our sample did not impact the interpretation of results due to the documentation of multivessel CAD in both sexes.</p>
      <p>Most men (63.29%) had a score <underline>&gt;</underline> 6 points, while in most women there was a score &lt; 6 points. The higher score for men may be related to the fact that the male sex already defines an additional score. In addition to that, myocardial infarction is more common in men, but women have a worse prognosis, due to higher rates of death and re-infarction<sup>31</sup>. As for chest pain, although it is more frequent in women, the prevalence of significant CAD is lower, causing a lower predictive value for non-invasivetesting<sup>32,33</sup>.</p>
      <p>The prognostic analysis did not consider the difference between double or triple vessel coronary angiographic patterns due to a low number of outcomes during follow-up.</p>
      <p>The mortality rate (10.33%) in our study was higher than the overall mortality of patients with stable angina, which is around 1% per year according to the guideline on stable angina<sup>33</sup>. This can be explained by the presence of a greater number of high-risk patients in our study, with higher prevalence of multivessel disease and diabetes, despite preserved left ventricular function. </p>
      <p>The incidence of combined events and the need for re-intervention with angioplasty after randomization was higher in the PTCA group. This is probably related to a higher rate of restenosis, as a representative portion of our sample has diabetes. Higher rates of restenosis are commonly found in patients with diabetes<sup>34</sup>. </p>
      <p>The high rate of diabetes (36.8%) also determined a higher baseline scoring. This is compatible with the fact that patients with diabetes have a higher incidence of severe coronary artery disease. It is well established that diabetes is a major risk factor for coronary events<sup>35</sup>. Type 2 diabetes is of particular importance because it is more common and often occurs in the elderly when multiple risk factors coexist. </p>
      <p>With respect to ET, patients with diabetes represent a particularized group: there is a higher incidence of hypertension, peripheral vascular disease, peripheral neuropathy, obesity and lower functional capacity. Moreover, they are more exposed to the use of drugs that limit heart rate. Thus, when multiple risk factors coexist, there are limitations to the achievement of a low risk in the Duke score. Additionally, the level of work achieved may not be sufficient for the documentation of myocardial ischemia, even with a significant CAD.</p>
      <p>The score of Hubbard was initially selected to compose the new score, as it contains variables that are easy to evaluate. The number of variables is small, the sum of points is simple and easy to interpret, having a linear correlation between the outcome and prognosis. Moreover, it can identify individuals at high risk, even when classified as low risk by the Duke score<sup>36</sup>. However, it has limitations, such as the exclusive analysis of clinical variables, not considering documentary evidence of myocardial ischemia which confirmedly provides additional prognostic information<sup>37</sup>. </p>
      <p>By adding this variable in the analysis, 31 patients were classified as low risk by the new scoring system, because they had a negative exercise testing. Thus, the Hubbard score may have overestimated the highest risk group in the population studied. </p>
      <p>In the ET, although other variables such as functional capacity, arrhythmias, inotropic and chronotropic responses, are thought to have higher predictive value than the ST-segment depression, there are flaws in the interpretation of several studies. It was not considered that in clinical practice a positive ET eventually influences the indication of cineangiocardiography and, consequently, pharmacological treatment or coronary artery bypass grafting (either surgical or percutaneous). Such therapeutic interventions determine a change in the natural history of coronary artery disease that impacts the prognostic value of electrocardiographic marker for myocardial ischemia.</p>
      <p>The prognostic analysis of the new score did not incorporate these specific variables of the ET, adopting only the presence of electrocardiographic documentation of myocardial ischemia, because the goal was to apply a practical system that was easy to remember and interpret, so it is more widely accepted by both the clinicians and experts.</p>
      <p>With the use of simplified prognostic scores used in combination with the ET, we can stratify more accurately the patients with stable coronary artery disease, reducing the rate of requests of high-complexity procedures.</p>
      <p>Scores improve the prognostic accuracy of the ET, reduce bias in interpretation and organize the various clinical information, determining a reduction in the subjectivity and variability in risk stratification. Particularly, the score proposed by this study demonstrated its prognostic value in a comprehensive manner through a simple and organized system. </p>
      <p>
        <bold>Conclusions</bold>
      </p>
      <p>This new score is a simple and objective method for risk stratification of stable coronary artery disease.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of doctoral submitted by Fernanda Coutinho Storti, from InCor - HCFMUSP.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
